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3About research method:  
“First record what you see and then 
investigate the functions of the observed 
form.” 
“Let us keep looking, in spite of everything. 
Let us keep searching. It is indeed the best 
method for finding, and perhaps, thanks to our 
efforts, the verdict we will give this patient 
tomorrow will not be the same as we must 
give him today.” 
Jean-Martin Charcot (1825-1893) (Charcot 1987) 
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Background 
Among outpatients presenting with physical symptoms, one third have been found to be not 
fully medically explained (Kroenke 2003). Modern history of Somatoform disorders (SDs) 
began in the 1960-70’s when the Hysteria disease was renamed to Briquet’s syndrome, after 
the work of Purtell et al. in 1951 (Purtell, Robins et al. 1951) and Perley and Guze in 1962 
(Perley, Guze 1962). With the introduction of the third edition of the Diagnostic and 
Statistical Manual of Mental Disorders, Third Edition (DSM)-III (American Psychiatric 
Association 1980) the category of Somatoform disorders (SDs) appeared and Briquet’s 
syndrome renamed into Somatization disorder (SDz). Diagnostic criteria of the SDs category 
were based the exploration of MUSs, and a 37-item symptom list was devised from the old 
59-item hysteria symptom list for examination of SDz (DeSouza, Othmer 1984; Katon, Lin et 
al. 1991). Although SDz was validated by the five Feighner criteria (Feighner, Robins et al.
1972), like other disorders of the DSM-III, the SDs criteria have mainly been descriptive, 
pragmatic and derived from consensus (First 2005). Since their introduction the SDs have 
been constantly been subjected to change in classification revisions, of both DSM-IV 
(American Psychiatric Association 1994) and International Classification of Diseases, Tenth 
Revision (ICD)-10 (World Health Organization 1993). Alternative diagnostic constructs and 
suggestions have increasingly been put forth along the way, and the Multisomatoform 
disorder (MSD) based on the exploration of current and not lifetime symptoms accepted in the 
primary care version of DSM (DSM-IV-PC) (American Psychiatric Association 1995). The 
ongoing debate of what to do with SDs in the future and the need for change (Wise, Birket-
Smith 2002) is at the moment quite compelling. All suggestions have been made, from, 
keeping the SDs category as today, (Hiller, Rief 2005; Hiller 2006), relocating it within the 
next DSM-V to “Psychological Factors Affecting Medical Conditions” category (Fava, Fabbri 
et al. 2007), moving it outside to Axis III, General Medical Conditions (Kroenke 2006) and 
even - radically - abolishing it altogether (Mayou, Kirmayer et al. 2005). With the increasing 
pressure of mental disorders and diagnoses to be more empirically based, the crucial question 
is whether there is enough evidence to justify their belonging to the realm of mental disorders 
or not (Rief, Isaac 2007).   
On this background this thesis has sought to contribute to the present SDs discussion, by 
elucidating the distinction of medically explained (MES) and unexplained symptoms (MUS), 
8and exploring differences in lifetime and current symptom criteria of SDs, exploring course 
and stability, overlap and comorbidity with anxiety, depression and musculoskeletal disorders 
and presenting prevalence based on newer suggested current MUSs criteria for the first time 
in Norway.  
Research questions 
The topic of the present thesis is on somatoform disorders (SDs) and their symptoms, i.e. 
medically unexplained symptoms (MUSs). The thesis endeavours to answer five main 
research questions. 
• How accurate is the recall of lifetime symptom data (both medically unexplained and 
explained), and what are the predictors for the failure at follow-up to recall symptoms 
reported previously at baseline, i.e. symptoms “lost”? (Paper I)  
• What is the course of medically unexplained pain (MUS-pain) (a disorder at the one-
symptom level) over time, and what are the predictors of recent MUS-pain? (Paper II)  
• What is the extent of overlap, or comorbidity, with anxiety and depression, what is the 
stability of SDs, and are there differences between SDs according to “lifetime” and 
“current” symptom criteria? (Paper III)  
• What are the prevalence rates of current SDs in Norway in 2001? (Paper IV) 
• Should current SDs be regarded as mental or physical conditions? Are risk factors of 
severe current SDs different from those of anxiety/depression and musculoskeletal 
disorders, and are there differences in psychological distress, utilization of health care 
and medication in the co-morbid subclasses of severe current SDs (Paper IV)? 
Material and methods 
The material of this thesis is based on two general population samples, of randomly drawn 
subjects 18 years or older, from two geographical areas in Norway (Lofoten, Northwest coast 
district and Oslo, Holmlia suburb area). The thesis consists of four papers I-IV. The three first 
(Paper I-III) are based on respondents interviewed with the Composite International 
Diagnostic Interview (CIDI) over a time span of 11 years (in 1990 at baseline and 2001 
follow-up), and the last (Paper IV) on new respondents CIDI interviewed in 2001.  
Paper I deals with the stability of lifetime MUSs and MESs, and the reliability of the 
MUS/MES distinction, as well as that of symptom recall. In Paper II the course of MUS–pain 
(representative of SDs at the one symptom level) is described, and factors related to chronicity 
and predictors of MUS-pain in 2001 explored. 
9Paper III and IV deal with the disorders of the SDs category. In Paper III, disorder 
discreteness and overlap are examined, and differences between SDs according to lifetime or 
current symptom criteria explored. Paper III also examines stability of SDs and comorbidity 
with anxiety and depression. In Paper IV, prevalence of current SDs in 2001 is presented and 
psychological distress examined by the Hopkins Symptom Checklist 25-item scale (HSCL-
25) in comorbid subclasses of SDs. Whether current SDs should be regarded as mental or 
physical conditions is discussed in Paper IV on the basis of the differences found in comorbid 
subclasses of SDs and differences in risk factors of current SDs, versus anxiety/depression 
and musculoskeletal disorders. 
Results 
A wide range of individual lifetime symptoms, from 22 to100%, were lost to recall at follow-
up. Recall was better when the number of symptoms was grouped (approx. 50% for 1 to 3 
symptoms). The large degree of measurement error was mainly due to faulty recall over time.  
Gender and age emerged as significant (P<.01) markers for MUSs-lost, and a decrease in 
physical morbidity for MESs-lost. Men tended to forget more symptoms than women, and 
younger respondents with high levels of baseline MUSs to remember slightly better at follow-
up. The transition of MUS to MES and visa versa over time was large, casting doubt about the 
reliability of the medically unexplained and explained distinction at when applied to lifetime 
symptoms.  
A small stable (present at baseline and present at follow-up) group of recent MUS-pain 
sufferers (8% out of all re-interviewed and 33.6% out of those with recent MUS-pain at 
baseline) was identified, almost all were women. Female gender was a significant (P<.05) 
marker, giving a twofold risk compared with men of having recent MUS-pain in 2001. Only 
co-morbid depression in 2001 and not the report of recent MUS-pain in 1990, remained a 
significant (P<.05) predictor, increasing the likelihood of having recent MUS-pain at follow-
up threefold (Paper II). 
Overlap for some disorders, such as PD and SDud was 100%, in both 1990 and 2001. 
Clear distinctions between individual SDs were very hard to make, except for a slight 
distinction being revealed between pooled “current SDs” and “lifetime SDs” (i.e. the SDs 
were pooled according to the MUSs criteria being either current or lifetime). Co-morbidity by 
OR ranged from 2.9 to 5.1 for depression and from 2.0 to 2.5 for anxiety. Co-morbidity was 
somewhat more pronounced for current SDs compared to lifetime SDs, and current SDs 4 
times more likely to occur among depressed respondents. Diagnostic stability was highest not
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for lifetime SDs but for current SDs (retrospective consistency; 42% for current SDs, 33.1% 
for lifetime SDs). Among individuals with a SD at baseline, 54% to 67% fulfilled the criteria 
of any SD at follow-up.  
The overall prevalence rate for pooled severe current SDs was 10%. Prevalence rates 
were generally twice as high for women. The main risk factor associated with severe current 
SDs was anxiety. Co-morbidity of severe current SDs with anxiety/depression and/or 
musculoskeletal disorders was 69%. Psychological distress in the subclass “only severe 
current SDs” (without any anxiety/depression/musculoskeletal co-morbidity) was 
significantly higher (P < .05) compared to respondents without disorders. Mental healthcare 
utilization among those with severe current SDs depended on the co-morbidity of 
anxiety/depression, and not on the SDs diagnosis alone. 
Conclusion 
Lifetime symptoms are often forgotten over time. Lifetime data elicited in community surveys 
by diagnostic instruments such as the CIDI should be viewed with caution. Methodological 
errors weakening the data credibility could lead to false impressions of true change over time. 
A distinction between medically unexplained and explained physical symptoms is difficult to 
maintain. 
A course of re-currency and remittance of MUS-pain is the rule rather than the 
exception. Except for a small group (mainly women) prone to chronicity, the prognosis of 
MUS-pain is relatively good. Clinicians should examine for depression when confronted with 
MUS-pain patients and be aware of the increased twofold risk for women compared to men to 
have debilitating pain symptoms over a long time. 
The prevalence rate of severe current SDs in 2001 is 10%. Prior depression and physical 
disease are risk factors for current SDs, whereas only prior anxiety is for lifetime SDs. Present 
anxiety is a main risk factor associated with severe current SDs. Overlap between different 
SDs is high (up to 100%). Diagnostic stability of current SDs is not much different to that of 
lifetime SDs. Current SDs are 4 times more likely to occur among depressed respondents and 
the comorbidity of severe current SDs with anxiety/depression and/or musculoskeletal 
disorders is 70%. 
Comorbid symptoms of anxiety/depression rather than medically unexplained symptoms 
per se, should qualify the patient for a psychiatric diagnosis. Disorders of the SDs category 
should be merged in future revised classifications. Future diagnostic criteria should be based 
on current rather than lifetime symptoms. 
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Preface 
The paradoxes of counting are many, we can count people but not individuals, and when 
numbers fail we usually collect more numbers, but counting the wrong thing gives no 
progress. For scientists, numbers are an international tool allowing us to speak the same 
language.  
However, this thesis is not only about the counting of symptoms. Motivated by my 
clinical experience as a psychiatrist in the field of psychosomatic medicine, from endless 
medical history taking and the counting of diverse medically unexplained symptoms in order 
to explore for the presence of somatoform disorder(s), this thesis is also about by the learning 
of the meaning behind such figures. Similar to my psychosomatic patients and their relentless 
search for reasons behind their symptoms and for better ways of coping, this research work is 
about arduous scientific probing, penetration and explanation.  
The beginning was in 2001, when I was offered a research grant in the Oslo-Lofoten 
mental health and general population follow-up study. The first year passed participating in 
the extensive collecting of data, interviewing and relocating “old” respondents from 1990, 
discovering how laborious the research task of longitudinal epidemiological studies was and 
how valuable the fundament made in 1990 by previous conscientious research colleagues was. 
Not only did I make telephone calls, obtain consent, make interview appointments, conduct 
computer based interviews in the afternoons and evenings, in diverse private homes or 
working places, but I also participated in the teaching programme and education of lay 
interviewers. In order to ensure the highest possible response rate, I was also faced with the 
challenge to travel, conducting several follow-up interviews with respondents who had moved 
to other parts of Norway. My contribution in the data collecting and punching from paper to 
statistical data program prompted my understanding of how important it was to ensure high 
quality raw data. Interrupted by a period of clinical work (2002 to 2003) at the Department of 
Psychosomatic Medicine, Rikshospitalet, I returned again to my research work in 2004. I am 
indeed grateful to all Oslo-Lofoten research colleagues for finalizing the collecting of 2001 
data under my leave of absence. On returning, the remaining research time was allocated to 
extensive 1990 and 2001 raw data analyses and to collaborative scientific article. The ultimate 
aim of my research work being to unravel a little more of the intriguing puzzle of medically 
unexplained symptoms and their related syndromes. Hopefully, when adding a new building 
stone of knowledge onto the existing one, the greater understanding in the end will contribute 
to an increased quality of psychosomatic medicine, to benefit of future patients.  
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1. Introduction and background 
This thesis is about physical complaints that cannot be fully explained by a known general 
medical condition, the direct effects of a substance or a medication. The terms applied in this 
thesis for such complaints and their related disorders will be medically unexplained symptoms 
(MUSs) and somatoform disorders (SDs). In order to understand the context and controversy 
in which MUSs and the category of SDs find themselves today, and to provide a background 
for the discussion of contemporary classification issues, a brief historical overview is needed, 
followed by a clarification of terms and a short depiction of where this field in medicine 
stands today.  
1.1 Historical background 
The roots of SDs and MUSs as we know them today, can be traced all the way back to ancient 
Greek and Egyptian medicine (Merskey, Merskey 1993; Trimble 2004) up to the downfall of 
Hysteria (Micale 1993) in the twentieth century.  
1.1.1 Ancient Greek medicine  
In the time of ancient Greek medicine, Hippocrates (460-370 BC) and Plato (428-347 BC), 
Hysteria was described as a condition afflicting women and the symptoms attributed to the 
uterus (Micale 1990; Merskey, Merskey 1993). Hence the disease name from Greek hystera,
the womb. Similarly Hypochondria was depicted as a disease afflicting mostly men and the 
symptoms attributed to the upper abdomen (Berrios 2001), again taking on the name from 
Greek hypochondrium, meaning the abdominal region underlying the rib cage. Mobility of 
abdominal organs was then believed to be the source of disordered emotions, and hysterical 
symptoms were explained by a wandering womb (Allison, Roberts 1994). The causal 
mechanisms of Hysteria were poetically and lavishly attributed to the arid (non menstrual) 
and angry womb, behaving like “an animal within an animal” and migrating around the body 
cavity exerting pressure on other organs, such as the liver and lungs (Merskey, Merskey 
1993). Although understood differently today, the medical names of diverse hysterical 
symptoms described from this time, for example feelings of suffocation or breathlessness 
(dyspnoe), loss of voice (aphonia) and lump feeling in throat (globus hystericus), pain during 
intercourse (dyspareunia) have lived on. 
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1.1.2 Sixteenth to nineteenth century 
With increasing anatomical knowledge from dissection of the human body in the 16th century 
by the great masters of anatomy such as Andreas Vesalius (1514-1564) (Vesalius 1968) and 
Leonardo da Vinci (1452-1519) (Cianchi 1998), ancient Greek theory of mobile body organs 
was gradually forsaken. Continuing this, a model of mental illness arose in the 17th century 
concentrated on the nervous system from the influential works of Thomas Willis (1621-75) 
and Thomas Sydenham (1624-89) (Trimble 2004). Even though a clear etiological shift was 
made, moving the anatomical placement of mental disorders from the body to the mind/brain, 
the Scottish physician Sir Robert Whytt’s (1714-66) still believed that hysteria affected 
females and hypochondria males (Berrios 2001; Trimble 2004). Alongside his discovery of 
the reflex, Whytt introduced the term “nervous” and divided patients with mental illnesses 
into three groups: the nervous, the hysterics and the hypochondriacs (Berrios 2001; Trimble 
2004). A broad etiological theory of all diseases being diseases of the nervous system, was 
further launched by William Cullen (1712-1766) and with nervous disorders being 
transformed to neurosis, Hypochondria was re-conceptualized into a form of insanity (Berrios 
2001).  
1.1.3 Nineteenth to twentieth century 
A landmark of extensive influence in the mid 19th century, which can be traced up to the 
somatoform diagnoses of today (see, 1.5 Classification of somatoform disorders) was the 
work of the French doctor Pierre Briquet (1796-1881) (Briquet 1859). Based on personal 
examination of about 450 patients Briquet described extensively the symptoms and treatment 
of Hysteria in 1859, as a condition of multiple physical symptoms with “pseudo-neurological” 
character having no clear medical (physical) evidence for the cause (Briquet 1859; Trimble 
2004). In contrast to earlier beliefs, hysterical symptoms were now clearly described to occur 
among men. 
In the late nineteenth century, often referred to as the “age of hysteria” the renowned 
French neurologist Jean-Martin Charcot (1825-1893), claimed that there was a female 
preponderance of Hysteria (ratio 1:20), and declared the cause to be neuropathological in 
males and psycho-pathological in females (Micale 1990). Similar to Briquet, Charcot believed 
Hysteria to be neurological and genetic in origin, and although bodily in symptomatology, 
seated in the mind or head. In his differential diagnostic struggle between epilepsy and 
hysteria, Charcot continued to uphold a strong association between hysterical symptoms and 
the reproductive organs for both genders (Charcot 1987; Micale 1990). As quoted from one of 
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Charcot’s famous Tuesday case demonstrations at the Salpêtrière Hospital in Paris on 
Hysteria (Charcot 1987):  
«….c'est toujours la chose genitale, toujours….»
(…it has always to do with the genitalia, always….) 
Directly influenced by his own medical theory, disease explanation and causation, 
Charcot, utilized hypnotic treatment techniques and developed technical genital compression 
devices, such as the “ovary corset” for his female patients, whereby physical external point 
pressure could be induced on particular body zones in the pelvic area, in order to start and 
stop hysterical fits (Micale 1990; Hermundstad 1999). 
Due to the experience of hypnotic abreaction techniques failing to relieve patients of 
their hysterical symptoms, Sigmund Freud (1856-1939), a former pupil of Charcot, turned to 
systematic analyses of the patient’s free associations (Gabbard 2004). Thus, in this strife to 
understand the symptoms of hysteria and the unconscious factors or etiological mechanism 
behind the symptoms, psychoanalytical theory was developed. A clear turning point in the 
history of medicine was hereby created, and emotions regarded as no longer seated in the 
body but in the brain. Although some of Freud’s original ideas have required revision, his 
theory has resulted in the evolution of modern psychiatry and neurosciences (Gabbard 2004), 
laying the foundation for the need to examine brain function, the mapping of conscious and 
unconscious memory and the emotional brain (LeDoux 1996). 
Fifteen years after his death, the diagnosis of Hysteria established by Charcot through 
rigorous clinical observation was officially denounced by his successor Joseph Bakinski 
(1857-1932) and colleagues of the Parisian neurological society (Micale 1993). A new 
concept and the re-ordering of symptoms with unknown disease pathology into groups of 
symptoms called “hysterical syndromes” were suggested as a replacement. A main reason 
behind this development was the discovery of the Spirochaetes bacterium, Treponema 
pallidum, in 1905 by the German bacteriologist Fritz Schaudinn (1871-1906) (Waugh 2005), 
giving Charcot’s followers the ability to differentiate neurosyphilis from other psychiatric and 
neurological diseases (Micale 1993). Since many of Charcot’s male hysteria cases came from 
the working class population, the likelihood of misclassified neurosyphilis was quite high. By 
the beginning of the twentieth century the Hysteria category had vanished completely from 
psychiatric nosologies (Micale 1993; Allison, Roberts 1994). Even so, the need for Hysteria’s 
reappearance has recently been advocated (Akagi, House 2002). 
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1.1.4 Briquet’s syndrome 
When Hysteria was renamed to Briquet’s syndrome in the 1960-70’s, the modern history of 
the SDs began. The background for the renaming was the research work of Purtell et al. in 
1951 (Purtell, Robins et al. 1951) and that of Perley and Guze in 1962 (Perley, Guze 1962). 
The reason for the renaming was to reduce controversy and avoid the pejorative implications 
associated with Hysteria (Guze, Woodruff, Jr. et al. 1972). Following the same principles as 
that described by Pierre Briquet in 1859, and taking on his name, Briquet’s syndrome was 
defined (Guze, Woodruff, Jr. et al. 1972) as:  
“A polysymptomatic disorder beginning early in life, characterized by recurrent or 
chronic ill health, presenting with dramatic, vague or complicated medical history. 
Characteristic features of the clinical history are many and varied pains, anxiety symptoms, 
gastrointestinal disturbances, urinary symptoms, menstrual difficulties, sexual and marital 
maladjustment, nervousness, mood disturbances and conversion symptoms. Frequent visits to 
physicians, excessive hospitalization and excessive surgery.”  
Diagnostic criteria were derived from this definition and checklist criteria based on 59 
symptoms distributed in 10 groups were presented in 1972 by Feighner et al. (Feighner, 
Robins et al. 1972). (See Appendix 1 for the symptom checklist criteria and grouping.) The 
diagnostic validation by the Feighner criteria (see also Table 1) which made Briquet’s 
syndrome eligible as a psychiatric disorder was based on 50 patients diagnosed with Hysteria 
in an observational study from 1951 (Purtell, Robins et al. 1951) and a follow-up study in 
1962, including a family study, consisting of 39 patients (Perley, Guze 1962; Guze 1967). In 
the follow-up sample, only 2 out of the 39 were men, and both men in addition had other 
diagnoses at follow-up. Similarly, Hysteria was diagnosed among 14% of the female relatives 
in the same female dominated sample. 
1.2 Somatization and somatoform
Under the strong influence of psychoanalytical theory, the term “somtization” was introduced 
in the beginning of the 20th century. The neologism “somatization” referring to the German 
word “Organsprache” first appeared in the writings of the Viennese psychoanalyst Wilhelm 
Stekel (1868-1940) and was first established by Stekel’s English translator JS van Teslaar in 
1925 (Marin, Carron 2002). The original meaning of “Organsprache” was “physical 
symptoms expressing physical conflict” - in content quite different from the 
psychoanalytically influenced somatization definition: “conversion of emotional states into 
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physical symptoms”. The concepts of early psychoanalytical theory posited that physical 
symptoms could be manifested in the body, as a reaction to unconscious conflicts of the mind. 
This bodily conversion concept, referring to the patient’s symbolic expression of mental 
distress as somatic symptoms, was further strengthened in the 1970s and 1980s by Kleinman 
(Kleinman 1977) and Lipowski (Lipowski 1987) and by Ford’s work with the introduction of 
the “somatizing” and SDs (Ford 1986). A definition of somatization which is still accepted 
today was proposed by Lipowski (Lipowski 1988), namely “a tendency to experience and 
communicate psychological distress in the form of somatic symptoms.” Although this 
process-orientated definition is still accepted today, it is not easy to operationalize, hence a 
second definition was put forth. Crucial to this definition was the absence of an underlying 
medical condition and the presence of psychological factors that were either causing or 
contributing to the symptom (Kroenke, Rosmalen 2006), thus establishing somatization and 
SDs according to the number of clinically significant medically unexplained symptoms 
(MUSs) (Kirmayer, Robbins 1991). 
1.3 Symptoms
The word symptom, derived from Latin sympt ma, and Greek sumpt ma, sumpt mata 
meaning “anything that has befallen one” is defined in the American Heritage dictionary as “a 
characteristic sign or indication of the existence of something else”(2000). Traditionally a 
symptom has been interpreted as “any sensation or change in bodily function experienced by 
the patient and associated with a particular disease”. Disease in this sense has in both the 
doctor’s and patient’s mind been connected with a physical disorder and a “medically 
explainable” anatomical or biological mechanism.  
Clear tissue pathology or biological correlates of symptoms have not always been so 
easy to find. In the struggle of putting aside the term hysteria and with the intent of studying 
somatization free from its legacy (Wool, Barsky 1994) by applying neutral terminology, the 
terms medically explained symptoms (MESs) and medically unexplained symptoms (MUSs) 
were introduced by Melville (1987) (Melville 1987). The identification of MUSs has in 
practice been done by exclusion, i.e. that which is left when the doctor cannot find any 
objective data or conventionally defined medical/physical disease to explain the patient’s 
complaints (Wessely, Nimnuan et al. 1999). The expressions “subjective health complaints” 
(Ihlebaek, Eriksen et al. 2002) and “functional somatic symptoms” (Wessely, Nimnuan et al.
1999) have also been used synonymously to MUSs.  
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Symptoms are the reasons why a person goes to the doctor and most of a physician’s 
professional life is spent dealing with symptoms (Komaroff 2001). More than one half of all 
outpatient encounters is reported to be due to symptoms, and out of these one half are pain 
complaints (Kroenke, Rosmalen 2006). Among outpatients presenting with physical 
symptoms, one fourth (20 to 25%) have been found chronic or recurrent and one third (33%) 
to be MUSs (Kroenke 2003). However, the dichotomous concept of physical symptoms being 
either explained by disease pathology or unexplained by mental illness or psychopathology, 
does not seem to fit so well any longer into modern medicine (Bradfield 2006). Symptoms-
based research is a growing field of scientific inquiry (Kroenke 2001), and knowledge 
concerning specific symptoms is increasing, for example with respect to chronic dizziness in 
neurology (Staab 2006), chronic pelvic pain, and dyspareunia in gynaecology (Dennerstein 
2005; Haugstad, Haugstad et al. 2006). Although diagnoses at the single one-symptom level 
have been warned against (Dennerstein 2005), for the patient, no matter what the cause or 
disease process, one or more very bothersome physical or mental symptoms are not only the 
sign(s) and the “something, indicating something else” but also the disease itself (Hahn 1999). 
The controversies over MUSs and “syndromes of MUSs”, be they mono– or poly 
symptomatic conditions, have increased over the past years, and issues concerning how to 
conceptualize, classify, validate, and name these conditions in the future have been  
undergoing vigorous debate (Wessely, Nimnuan et al. 1999; Wise, Birket-Smith 2002; 
Wessely, White 2004; Hiller, Rief 2005; Mayou, Kirmayer et al. 2005; Fink, Rosendal et al. 
2005; Rosendal, Fink et al. 2005; Binik 2005; Bradfield 2006; Kroenke 2006; Sykes 2006; 
Sharpe, Mayou et al. 2006; Starcevic 2006; Rief, Henningsen et al. 2006; Creed 2006b; Fink, 
Toft et al. 2007). Not only do symptoms still continue to puzzle, but also to constantly split 
the medical field in a “mind or body” approach (White, Moorey 1997; Komaroff 2001). In 
spite of an integrated biopsychosocial approach having won acceptance (Engel 1997), the 
controversy between “organic” or “functional” disease-states still seems to linger at the 
bedside. 
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1.4 Terms and definitions
Terms relevant to this thesis, definitions and nomenclature related to SDs and their symptoms 
are further clarified below.  
1.4.1 Medically explained and unexplained symptoms  
In view of the fact that the Somatoform Section of the Composite International Diagnostic 
Interview (CIDI), used in the studies of this thesis, is based on the probing and exploration of 
clinically significant physical symptoms, categorizing them as either MES or MUS, with the 
intent of these terms being neutral, the terms MES and MUS corresponding to the definitions 
by Melville (Melville 1987) will be used in this thesis:  
i) MES(s) – symptom(s) which can be attributed to a valid disease or known pathological 
mechanism. 
ii) MUS(s) – symptom(s) which cannot be attributed to any known valid disease or 
pathological mechanism. 
1.4.2 Somatization 
For the purpose of research, three forms of somatization have been identified by Kirmayer 
and Robbins (Kirmayer, Robbins 1991), namely i) high levels of MUSs, ii) levels of somatic 
preoccupation or illness worry beyond what is expected for demonstrable disease and iii) 
predominantly or exclusively somatic presentation of  psychiatric disorder, most commonly 
depression and anxiety. In this thesis somatization will be used according to definition i) 
above, i.e. as high levels of MUSs.  
1.4.3 Psychiatric epidemiology 
Psychiatric epidemiology can be defined as the study of mental illness in populations. The 
essence of all epidemiology is about what to measure and how to measure it. A good 
psychiatric epidemiological study depends not only on the selection of a representative and 
suitable population sample, but on a valid, reliable and usable case definition, and case 
establishment as well as the identification of relevant risk factors.  
1.4.4 Disease, illness, disorder, syndrome, functional, organic, comorbidity  
According to the Merriam-Websters Online Dictionary (2005) the above terms can be defined 
as:
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Disease: a condition of the living animal or plant body or of one of its parts that impairs 
normal functioning and is typically manifested by distinguishing signs and symptoms 
Illness:  an unhealthy condition of body or mind - synonymous to malaise: a generalized 
feeling of discomfort, or lack of well-being that can be associated with a disease state. 
Disorder: an abnormal physical or mental condition (noun) 
Syndrome: a group of signs and symptoms that occur together and characterize a particular 
abnormality or condition or a set of concurrent things (as emotions or actions) that usually 
form an identifiable pattern 
Functional: affecting physiological or psychological functions but not organic structure
Organic: relating to, or arising in a bodily organ – organ: a differentiated structure (as a heart, 
kidney) consisting of cells and tissues and performing some specific function 
Comorbidity: refers to the co-occurrence of disorders within persons, i.e. two or more distinct 
concurrent disorders, occurring in the same person at the same time.  
In the 19th century the terminology: “nervous and mental diseases” was customary, 
based on the assumption that organic origins would soon be found (Taylor 1983). However, 
since this has not uniformly been the case, the terms mental illness or disorder are found more 
appropriate expressions in today’s medicine. The term disorder is applied to those conditions 
where function is altered without identifiable morphological change, often implying an 
unknown or psychological cause. In other words disorder implies a dysfunction, resulting in 
the individual being at risk for experiencing harm – in the form of distress or disability 
(Wakefield, Spitzer 2002). Distress refers to the consciously perceived painful effects of the 
condition and disability to the extent that the condition interferes with social expectations, 
work or activities. 
The term illness is broader than disease and disorder since it also includes the patient’s 
experience, in addition to the physician’s biomedical disease concept (Longstreth 2005). On 
the other hand since the patient presents with his/her illness by bringing to the doctor their 
own idiosyncratic expressions, illness can only be a partial representation of any particular 
disease or disorder (Trimble 2004). The term syndrome implies a more complex bio-psycho-
social disease concept, in that it applies a set or group of symptoms (symptoms of either 
bodily/organic and/or psycho-social/emotional character) which collectively define or 
characterize a disease or disorder. In the field of psychiatry syndromes are in effect the 
clinical representations of illness (Trimble 2004). The term functional, has implied meaning 
no demonstrable organic basis (for example,  “functional somatic symptoms”) (2001) or been 
used as an synonym for a mental disorder (Trimble 2004). When asked about diverse 
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diagnostic labels, including the terms “functional”, “medically unexplained”, 
“psychosomatic” and “hysterical”, patients have preferred the term “functional” (Stone, 
Wojcik et al. 2002). Today, functional is recommended used in contemporary medicine to 
indicate an altered function in the nervous system and not as a synonym for psychogenic or a 
mental disorder  (Trimble 1982). For example in Functional Gastrointestinal Disorders 
(FGID) (Jones, Crowell et al. 2007), functional implies a complex malfunctioning or 
disturbance of the gut in, myogenic, neural and hormonal control mechanisms also involving 
psychosocial factors and emotional functioning. The term organic, implying a biological 
origin and basis, has often been used as the antonym of functional. The term organic mental 
disorder is still used in ICD-10, and applied to such disorders as delirium and dementia. 
However, organic is not applied in DSM-IV, due to the incorrect implication that other mental 
disorders have a non-biological basis. The term comorbidity referring to the possibility of 
different diseases occurring simultaneously in the same person will be used synonymously to 
co-occurrence and concurrent (Krueger 2002).     
In this thesis the terms mental disease, illness, disorder and syndrome will be used 
synonymously (Taylor 1983). The terms functional and organic will be used when relevant in 
the background literature, discussion and/or to future suggested diagnostic changes. 
1.4.5 Psychiatric taxonomy, diagnostic validity, reliability and utility 
Psychiatric taxonomy refers not only to the classification of mental illness and disorders but 
also to the principles underlying the classification. The term “taxon” meaning “class, category 
or type” with plural “taxa” is increasingly used in the ongoing DSM-V diagnostic debate 
(Joiner, Jr., Schmidt 2002). Given a new taxon, the improvement of the taxonomy has been 
suggested judged by whether it is i) more comprehensive, ii) easier to use, iii) deals better 
with the issues of “clinical significance”, iv) has a higher reliability, and v) has a higher 
validity (Kendell 2002).  
Validity in science has generally been accepted to mean “the nature of reality” (Kendell, 
Jablenski 2003). Formal criteria for establishing the validity of a mental disorder were first 
described by Robins and Guze (Robins, Guze 1970) and later known as the Feighner criteria
(Feighner, Robins et al. 1972) when introduced together with DSM-III. The five-step process 
given in Table 1, has dominated to date as the gold standard for establishing validity of a 
mental disorder or diagnostic class (Beauchaine, Beach 2006). An adaptation of the Feighner 
criteria into antecedent, concurrent and predictive validators were later presented by Kendler 
(Kendler 1980) and additional external validators, including modern genetics and 
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neurosciences by Andreasen (Andreasen 1995), see Table 1. Validation by course of the 
disease, preceding that of disease onset has also been emphasized (Panzetta 1974), as well as 
making validation progress by understanding the relationship between the concepts of 
dysfunction, disability and distress (Wakefield, Spitzer 2002).  
Table 1. Diagnostic construct validity and Feighner criteria   
The Five Feighner Phases: Diagnostic validity - establishing a clinical syndrome by:
1. Clinical description Cluster of symptoms and etiologic precursors 
2.  Laboratory studies Reliable physiological, biological and/or psychological markers 
3. Delimitation from other disorders Readily definable exclusionary criteria 
4. Follow-up study Predictable course 
5. Family Study Increased rates of the same disorder among first-degree relatives  
Type of validators:
1.  Antecedent 
Familial aggregation, premorbid personality, demographic, 
precipitating factors 
2. Concurrent Tests, including psychological tests 
3. Predictive 
Diagnostic consistency over time,  rates of relapse and recovery, 
response to treatment 
4. Additional external  
Molecular genetics and biology, neurochemistry, neuroanatomy, 
neurophysiology, cognitive neurosciences  
Validity of a diagnosis refers to the adequacy with which it reflects the clinical reality and 
medical knowledge about the condition. Validity is often described from several aspects, for 
example a mental disorder can be accredited as valid by: 
i) Face validity – the extent of obviousness, how easy the disorder is recognized clinically 
ii) Content validity – the extent to which all component elements of the disorder (as 
conceived) are measured 
iii) Consensual validity – the extent to which experts agree on how real the disorder is  
iv) Criterion (or concurrent) validity – the extent to which the disorder coincides with the 
“gold standard criterion”, i.e. a standard believed to be true   
v) Predictive validity – the extent to which the disorder has a typical outcome, course, 
prognoses, complications or treatment response.  
vi) Construct validity – the extent to which the disorder can be verified by an underlying 
construct or causal mechanism/etiology (or genetics) 
In summary, diagnostic validity has been defined by Beauchaine and Beach 
(Beauchaine, Beach 2006) as the extent to which a symptom criterion set identifies a non-
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arbitrary class of individuals who suffer from a single condition that confers increased risk of 
morbidity, mortality and/or psychological distress.  
Reliability of an instrument or test can be defined as the capacity to give the same result. 
Diagnostic reliability in this thesis will be explored by i) prospective consistency: the extent 
to which the diagnoses at baseline are the same at follow-up and ii) retrospective consistency: 
the extent to which the diagnoses at follow-up were the same at baseline. 
Since the study of mental disorders generally struggle with issues of low validity, 
diagnostic utility (or usefulness) defined as the essence of what the diagnosis conveys 
regarding course, outcome, and aetiology (Kendell, Jablenski 2003) also is vital. In addition to 
utility, diagnostic discreteness or the finding of a “point/zone of rarity” which discriminates or 
separates the disorder from other neighbouring disorders also is a tool in the work to attain a 
more valid taxonomy (Kendell 2002). Although schizophrenia has been demonstrated to have 
such a zone of rarity or discontinuity, discriminating it from other psychiatric syndromes, this 
has not been so easy to demonstrate for other psychiatric syndromes (Kendell 2002).  
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1.5 Classification of somatoform disorders
The category of SDs appeared for the first time in the Diagnostic and Statistical Manual of 
Mental Disorders, Third Edition (DSM)-III (American Psychiatric Association 1980). The 
first disorder in the whole SDs category was Somatization disorder (SDz), the renamed multi- 
or polysomptomatic equivalent to Briquet’s syndrome (DeSouza, Othmer 1984). A reason for 
the re-naming and re-classification was to separate Briquet’s syndrome from conversion, Pain 
disorder (PD) and Hypochondriasis (HC) (DeSouza, Othmer 1984). Simultaneously, the 
grouping of symptoms in SDz were re-organized into seven domains (sickly; conversion or 
pseudoneurological; gastrointestinal; female reproductive; psychosexual; pain; 
cardiopulmonary) and the 59-item symptom list of Briquet’s syndrome reduced to 37 by 
committee consensus (DeSouza, Othmer 1984; Katon, Lin et al. 1991). Physical symptoms 
related to major depression were eliminated, and the number of MUSs required for SDz, 
reduced compared to Briquet’s syndrome and set at fourteen for women and twelve for men.  
Due to the very stringent criteria of SDz in DSM-III, Undifferentiated Somatoform 
Disorder (SDud) with the criteria of at least one MUS was added to the of DSM-III, Revised 
Edition (DSM-III-R) (American Psychiatric Association 1987) in 1987. In each revision of 
DSM number of diagnoses has grown substantially (Follette, Houts 1996). In the mid 1990’s, 
Body dysmorphic disorder and Somatoform disorder not otherwise specified (SDnos), 
appeared in the DSM, Fourth Edition (DSM-IV) (American Psychiatric Association 1994), as 
substitutes of the previous DSM-III, Atypical somatoform disorder.  In contrast to number of 
disorders steadily having increased by each diagnostic revision, the number of MUSs required 
for SDz has decreased. The MUS requirement was by the DSM-IV reduced to six symptoms 
and to eight by the International classification of diseases, Tenth Revision (ICD)-10 (World 
Health Organization 1993) (see Table 2 ). SDnos described by the DSM-IV, Text Revision
(DSM-IV-TR) (American Psychiatric Association 2000) included the criteria of MUSs of less 
than 6 months duration. Criteria of SDs in DSM-IV-TR and SDs including Dissociative 
[conversion] disorders in ICD-10 are given in Table 2, revealing also the differences between 
the two classification systems. A criterion introduced by the DSM-IV was that of “clinical 
significance”(Regier, Narrow 2002), i.e. the SDs and their symptoms should cause marked 
distress or significant interference with social, occupational or other areas of functioning.  
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Table 2. Somatoform and dissociative (conversion) disorders in DSM-IV and ICD-10 
DSM-IV Somatoform disorders (SDs) ICD-10 Somatoform disorders (SDs) F45 
Somatization disorder (SDz): 300.81 Somatization disorder (SDz): F45.0
- a history of many MUSs before age 30 
- resulting in treatment sought or 
psychosocial impairment 
- a total of 8 or more MUSs in groups I-IV, 
at least 4 pain, 2 gastrointestinal, 1 sexual, 
1 pseudoneurological (33-item MUS list)    
 - at least 2 year history of MUSs 
- resulting in repeated (3 or more) primary care 
or specialist consultations 
- a total of 6 or more MUSs, from at least 2 
separate organ groups I-IV (14-item MUS list) 
I Pain (10)  I Gastrointestinal (6)  
II Gastrointestinal (5)  II Cardiovascular (2)  
III Sexual (5)  III Genitourinary (3)  
IV Pseudoneurological (13)  IV Skin and pain (3)  
Undifferentiated somatoform disorder 
(SDud)
300.81 Undifferentiated somatoform disorder (SDud) F45.1 
Hypochondriasis (HC) 300.7 Hypochondriacal disorders (HC) F45.2 
    
Pain disorder associated with psychological 
factors (PD) 
307.80 Persistent somatoform pain disorder (PD)  F45.4 
- acute  -  
- chronic  (chronic)  
Pain disorder associated with both 
psychological factors and a general medical 
condition  
307.89   
- acute    
- chronic    
Pain disorder associated with a general 
medical condition 
   
-  Other somatoform disorders F45.8 
Somatoform disorder not otherwise 
specified (SDnos)  
300.82 Somatoform disorder, unspecified (SDnos) F45.9 
-    
-  Somatoform autonomic dysfunction F45.3 
Body dysmorphic disorder 300.7 Hypochondriacal – dysmorphophobia F45.2 
    
Conversion disorder  300.11 Dissociative [conversion] disorders F44 
  - dissociative amnesia F44.0 
  - dissociative fugue F44.1 
  - dissociative stupor F44.2 
  - trance and possession disorders F44.3 
- with motor symptom or deficit  - dissociative motor disorders F44.4 
- with seizures or convulsions  - dissociative convulsions F44.5 
- with sensory symptom or deficit  - dissociative  anaesthesia and sensory loss F44.6 
- with mixed presentation    - mixed dissociative disorders F44.7 
  - other dissociative disorders F44.8 
  - dissociative disorder, unspecified F44.9 
    
(- Chronic fatigue)   (Neurasteni F48.1) 
1.6 Sub-threshold somatoform disorders and alternatives 
The problem of the SDs category of disorders being either too narrow or too broad in criteria, 
has further been manifested by several alternative diagnostic constructs of SDs with even less 
numbers of MUSs put forth along the way (Trimble 2004). For example, the Abridged 
Somatoform Disorder (SSI-4/6) (Escobar, Burnam et al. 1987) based on the fifteen item 
symptom list Somatoform Symptom Index (SSI) (Escobar, Rubio-Stipec et al. 1989; Escobar, 
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Waitzkin et al. 1998)used four MUSs for men and six for women, hereafter referred to as SSI-
4/6. This DSM-III-R based SSI-4/6 construct has since been recommended modified to a SSI-
3/5 (three MUS for men and five for women) equivalent for DSM-IV (Rief, Heuser et al.
1996).  
Due to the critique that symptom lists are not being empirically derived and fail to take 
into account other factors such as illness behaviour, a diagnostic concept named 
“Polysymptomatic somatoform disorder” was launched (Rief, Hiller 1999). Multi-axial SDs 
classification approaches and other criteria in addition to number of MUSs, such as degree of 
psychosocial impairment, attribution of symptoms, ongoing physical disease, associated 
anxiety and depression, have also been proposed (Wessely, Nimnuan et al. 1999).  
In order to facilitate criteria based diagnoses of mental disorders in primary care the 
PRIME-MD (Pfizer Inc, New York, NY) instrument was developed (Spitzer, Williams et al.
1994). The assessment of eight commonly occurring mental disorders in primary care were 
based on a self-administered Patient Health Questionnaire (PHQ), out of which a 15-item 
somatic symptom subscale (the PHQ-15) (Kroenke, Spitzer et al. 2002) was derived for the 
screening of somatoform disorder. The PHQ-15 (see Appendix 2) screens for 15 physical 
symptoms occurring during the last month on a severity scale from 0- not bothered, 2- 
bothered a little to 3-bothered a lot, making no distinction between explained or unexplained 
(Kroenke, Spitzer et al. 2002). Since the somatization disorder was far too  complicated for 
use in primary care, the Multisomatoform disorder (MSD) (Kroenke, Spitzer et al. 1997) was 
introduced (see Table 3). In contrast to earlier diagnoses of SDs being based on lifetime
symptomatology the MSD was based on three current (within the last one month) MUSs 
combined with at least one lifetime MUS (with duration at least 2 years). The MSD has since 
been recognized by the primary care version of DSM-IV (DSM-IV-PC) (American 
Psychiatric Association 1995) and the criteria of the disorder based on the exploration of 
fifteen symptoms (14 symptoms for men and 15 symptoms for women) by the PHQ-15 (see 
Appendix 2).   
Recently the MSD has been recommended modified into a Physical symptom disorder 
(PSD) (Kroenke 2006) and the symptom criteria again reduced to a disorder at the one 
symptom level (see Table 3). In accordance with an earlier controversial proposal to do away 
with the SDs category altogether (Mayou, Kirmayer et al. 2005), the PSD has been suggested 
moved to Axes III (the axes in DSM for coding relevant General medical conditions) of future 
DSM-V (see Table 3).  
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Other collective terms such as “Common distress disorders” (Henningsen, Zimmermann 
et al. 2003) and  “Psychosomatic distress syndromes” (Starcevic 2006) for all somatization-
spectrum conditions have also been suggested. Recently a “Bodily distress disorder” (Fink, 
Toft et al. 2007) has been promoted, based on factor analyses of multiple symptoms falling 
into three categories; cardiopulmonary, gastrointestinal and musculoskeletal tension or pain. 
Furthermore, it has been suggested that the already existing section, “Psychological Factors 
affecting Medical Conditions” in DSM-IV be designated as a new section in future DSM-V to 
include the 7 disorders: hypochondriasis, disease phobia, persistent somatization, conversion 
symptoms, illness denial, demoralization and irritable mood (Fava, Fabbri et al. 2007). 
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Table 3. Diagnostic criteria of multisomatoform and physical symptom disorder  
Multisomatoform Disorder (MSD) 
A. Three or more somatoform symptoms a currently present (i.e. within the past month)
B. A somatoform symptom meets with criterion 1 or 2: 
  1. After appropriate investigation, the symptom cannot be fully explained by a known general 
medical condition or the direct effects of a substance (e.g. a drug abuse or a medication) 
  2. When there is a related general medical condition, the physical complaint or resulting social or 
occupational impairment is in excess of what would be expected from the history, physical 
examination, or laboratory findings.  
C. The symptoms cause clinically significant distress or impairment in social, occupational, or other 
important areas of functioning. 
D. Although specific symptoms may come and go, the person has had one or more somatoform 
symptoms, for more days than not, for at least 2 years. 
E. Criteria for somatization disorder are not met nor are the symptoms part of the diagnostic criteria 
for a mental disorder that is currently present (e.g., fatigue or insomnia in a patient with a depressive 
disorder or chest pain and dizziness that only occur during a panic attack in a patient with a panic 
disorder). 
F. The symptoms are not intentionally produced or feigned (as in factitious disorder or malingering). 
Physical Symptom Disorder (PSD) 
1. Key diagnostic criteria for PSD:
a. One or more physical symptoms b currently present and causing impairment in social, 
occupational, or other important areas of functioning.   
b. Symptoms are not fully explainable by another medical or psychiatric disorder, with the 
exception of syndromes manifested solely by symptoms (e.g. irritable bowel syndrome, fibromyalgia, 
tension headache, chronic fatigue syndrome, temporomandibular disorder, interstitial cystitis, etc.)  
c. Duration of at least 6 months
2. Additional specifiers: 
a. Severity of somatic symptom burden can be graded as mild, moderate or severe according to 
PHQ-15 a total 0-30, scores of (5-9) mild, (10-14) moderate or greater (15-30) severe.  
b. Type of symptoms or symptom syndromes can be specified (e.g., lumbago, dizziness, irritable 
bowel)  
3. Resides on Axes III
4. Replaces several somatoform disorders: somatization disorder, undifferentiated somatoform 
disorder and pain disorder. 
a
 Primary care evaluation of mental disorders and use of PHQ-15 item symptoms list (Kroenke, 
Spitzer et al. 1997; Kroenke, Spitzer et al. 2002) 
b
 Physical symptoms according to the PHQ-15 symptom list (Kroenke, Spitzer et al. 2002) 
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1.7 Characteristics of somatoform disorders
Considering all the classification dilemmas and the continuous change of SDs since their very 
beginning, what do we know about SDs today and how can we identify and measure the 
phenomena of SDs as accurately as possible? How are SDs classified today? What do we 
know about prevalence rate, course over time, diagnostic stability, risk factors and co-
morbidity of SDs, and what do we not know?   
1.7.1 Diagnostic features  
The common criterion for all SDs as classified today in both DSM-IV (American Psychiatric 
Association 2000) and ICD-10 (World Health Organization 1993) is the screening of MUSs. 
The diagnostic characteristics are, however, quite different in both content and criteria in the 
two systems Table 2. The differences are manifested clearly in the SDz entity; for example 
pseudoneurological symptoms are included in DSM-IV but in ICD-10 this symptomatology is 
kept in the Dissociative (conversion) disorder (F44) category. A common feature of SDs in 
both DSM-IV and ICD-10 is that criteria range from detailed numbers and combination of 
MUS from different organ/body parts in SDz, down to very lax criteria with only one 
clinically significant symptom being required, in for example SDud or chronic Pain Disorder 
(Persistent somatoform pain disorder) (PD). Other shared conceptions are those of long 
lasting or lifetime perpetuating symptoms combined with adverse healthcare seeking 
behaviour. 
1.7.2 Symptom screening and symptom lists  
Even though it has been convincingly argued that the pure counting of clinically significant 
MUSs using checklists is descriptively insufficient (Fink 1996; Burton 2003) in the 
diagnosing of the MUS-syndromes (Sharpe 2002), this has remained the core criteria of  SDs 
for decades. Many symptoms used in the symptom lists of today have remained almost 
unchanged since their introduction in the diagnosing of Hysteria (Feighner, Robins et al.
1972) (see Appendix 1 for diagnostic criteria of Hysteria, and the overview of MUS screening 
by symptom-lists given in Table 4.) 
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Table 4. Symptom-lists used for establishing diagnoses of somatoform disorders 
WHO-CIDI 
version 1.2 
DSM-IV ICD-10 PHQ-15 Hysteria 
(Briquet’s 
syndrome) 
Number of symptoms 43 33 14 15 59 
Time frame Lifetime  
and pooled 
current a
Lifetime Lifetime Last 
month 
Lifetime 
i) Pain a:      
1. abdominal pain  X X X X X 
2. back pain X X  X X 
3. joint pain  X X X &4 X &4 X 
4. leg/arm (extremity) pain  X X   X 
5. chest pain  X X X X X 
6. headache  X X  X X 
7. painful menstruation (dysmenorrhoea)* X X  X X
8. urination pain (dysuria) X X X &33  X 
9. genital (rectum) pain  X X X  X 
10. other place pain  X    X 
ii) Gastrointestinal and pseudo-neurological a:      
11. vomiting (other than pregnancy) X X X  X 
12. continuous vomiting during pregnancy* X X   X 
13. nausea X X X X &15+16 X 
14. diarrhoea  X X X X &45 X 
15. excessive gas (bloating) X X X  X 
16. food intolerance X X   X 
17. blindness X X   X 
18. blurred vision X    X 
19. deafness X X   X 
20. trouble walking (balance) X X   X 
21. numb feeling in arm/leg (anesthesia) X X X & 35  X 
22. paralysis X X   X 
23. lost voice (aphonia) X X   X 
24. seizures (convulsions) X X   X 
25. fainting spells X   X X 
26. unconscious X X   X 
27. amnesia X X   X 
iii) Sexual and other symptoms a:      
28. double vision  X X    
29. short breath  X     
30. weakness (fatigue) X   X X 
31. blotchiness or discoloration of the skin  X  X   
32. bad taste in mouth  X  X   
33. urinate too often  X     
34. unable to urinate (urinary retention) X X   X 
35. numbness (paresthesia)  X    X 
36. lump in throat X X   X 
37. irregular menstruation* X X   X 
38. excessive menstrual bleeding* X X   X 
39. sexual problems, impotence (frigidity)  X X   X 
40. sexual indifference  X X   X 
41. pain during sexual intercourse (dyspareunia)  X X  X X 
42. sex not enjoyable  X     
43. often felt sickly  X    X 
44. hallucinations   X   X 
45. constipation      X 
46. dizziness     X X 
47. feeling your heart pound or race (palpitations)    X X 
48. shortness of breath   X X X 
49. sleeping trouble    X  
50. unusual copious or vaginal discharge*    X   
a
 Recency of MUS(s) [occurring during last month, last six months, over six months ago and within last year or 
over one year ago] explored pooled into 3 categories: i) pain, ii) gastrointestinal and pseudo-neurological, iii) 
sexual and other symptoms 
* women only  
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1.7.3 Prevalence   
Nearly one third of all symptom complaints in the general population have been found to be 
either psychiatric or inexplicable (Kroenke, Price 1993). Since physical symptoms are so 
frequent in the general population and in their less severe manifestation almost a naturally 
occurring phenomena (Ihlebaek, Eriksen et al. 2002), one can question whether screening and 
diagnosing multitudes of diverse symptoms without any clear cut physical detectable cause, is 
at all meaningful (Kroenke, Harris 2001).  
Contrary to symptoms being prevalent in the general population, the initial report of 
prevalence rate of SDz according to DSM-III criteria from the large Epidemiologic 
Catchment Area (ECA) study (1991) was very low, 0.1% to 0.38% (Swartz, Blazer et al.
1986; 1991). Prevalence rates of SDz by DSM-III/DSM-III-R from other studies have been 
very low from 0.1% to 1% (Canino, Bird et al. 1987; Bland, Orn et al. 1988; Wells, Bushnell 
et al. 1989; Kirmayer, Robbins 1991; Wittchen, Essau et al. 1992; Faravelli, Salvatori et al. 
1997). Subsequently the disorder was completely dropped in the National Comorbidity 
Survey (NCS) in both 1994 (DSM-III-R) and 2005 (DSM-IV) (Kessler, McGonagle et al.
1994; Kessler, Chiu et al. 2005). Then very low prevalence rates of SDz resulted also in many 
researchers abandoning the DSM-III criteria, in favor of more practical definitions with lower 
symptom threshold. Consequently, prevalence rates according to the abridged SSI-4/6 
construct were reported ranging from 4.4% to 20% (Escobar, Burnam et al. 1987; Escobar, 
Rubio-Stipec et al. 1989; Kirmayer, Robbins 1991). Although the symptom threshold for SDz 
in DSM-IV are more lenient, prevalence rates are still not high, ranging from 1% to 1.4%  
(Simon, Gureje 1999; Lynch, McGrady et al. 1999) and by ICD-10 up to 10.1% (Toft, Fink et 
al. 2005). PD has been reported as the most frequent SD (Wittchen, Essau et al. 1993), and 
overall prevalence rates for the whole group of SDs reported ranging from 12.6% to 16.1% 
(Lieb, Pfister et al. 2000; De Waal, Arnold et al. 2004). Prevalence reports of SDud have also 
varied greatly, from 13% to 79% (Faravelli, Salvatori et al. 1997; Lynch, McGrady et al.
1999; De Waal, Arnold et al. 2004). 
In Norway, studies utilizing the CIDI (Robins, Wing et al. 1988), have assessed the 
overall twelve-month prevalence rates of SDs for the adult population (over 18 years) by 
DSM-III-R to be 2.1% to 2.2% in the period 1994 to1997 (Kringlen, Torgersen et al. 2001; 
Kringlen, Torgersen et al. 2006), while the overall two-week prevalence rate by ICD-10 
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research criteria from the first cross-sectional data of the Oslo-Lofoten study in 1990 was 
5.9% (Somatoform disorder not otherwise specified (SDnos), was not included) (Sandanger, 
Nygard et al. 1999). A recent 27-European country survey with Norway included (Wittchen, 
Jacobi 2005) based on the CIDI estimated the 12-month prevalence rate of the whole SDs 
category across all 27 countries to be 18.7%, by either DSM-III-R/DSM-IV or ICD-9/ICD-10.  
Prevalence rates for alternative constructs of SDs based on current symptom criteria, 
such as MSD have been estimated to range from 8% to 24% (Kroenke, Spitzer et al. 1997; 
Lynch, McGrady et al. 1999). A large German population survey (2,552 persons) assessing 
current SDs (with severe impairment at the one symptom level) recently reported a 22% 
prevalence rate (Hiller, Rief et al. 2006). For the newly suggested PSD construct (Kroenke 
2006) prevalence rates and validation against DSM criteria are lacking.  
Due to the multiplicity of definitions and diverging research methodologies, past 
prevalence rates of SDs have been criticized for being incomparable (Creed, Barsky 2004) 
and the need for longitudinal population based surveys concerned with SDs has been 
underlined, as well as the need for improved diagnostic accuracy (Creed 2006a).  
1.7.4 Course and stability 
Sixty-one percent of lifetime MUSs detected at baseline have been found to be forgotten at 
follow-up after only 12-months (Simon, Gureje 1999). The consequences of such a large 
instability of lifetime MUSs recall, and thereby an inaccurate counting of lifetime MUSs, 
would be very unstable and imprecise prevalence estimates of SDs derived from structured 
interviews. 
The percent re-diagnoses of SDs by CIDI and in the whole DSM-IV group, has been 
found at 3½ year follow-up to be 48% (Lieb, Zimmermann et al. 2002). Stability of DSM-III 
disorders in other studies has been rated higher, with about two thirds of patients meeting the 
same diagnostic criteria after 4-5 years (Kent, Tomasson et al. 1995; Barsky, Fama et al.
1998). For SDz according to DSM-IV, a very low percent of re-diagnosis (28%) was found at 
one year follow-up (Simon, Gureje 1999). 
Although some information does exist concerning course over time as described above, 
our knowledge is still limited due to the general sparseness of follow-up studies, especially 
long-term, 10 year or more, follow-up studies. Since criteria of the newer suggested PSD 
(Kroenke 2006) have a symptom threshold of “at least one” and the recommended 15-item 
physical symptom list used to examine for MUS includes pain symptoms, examining the 
course over time at the one symptom level (such as course of MUS-pain) is highly relevant.     
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1.7.5 Overlap and comorbidity  
Multiple unexplained symptoms have been reported 50% comorbid with depression and 11% 
of depressed patients have been found to deny having psychological symptoms of depression 
(Simon, VonKorff et al. 1999).  
Overlap between existing individual functional syndromes (such as chronic fatigue, 
fibromyalgia, irritable bowel syndrome, multiple chemical sensitivity, tension headache, 
interstitial cystitis, post-concussion syndrome) has been considered so substantial that 
similarities outweigh the differences between them (Wessely, Nimnuan et al. 1999; Aaron, 
Buchwald 2001). 
Generally a very high (79%) comorbidity of lifetime mental disorders has been reported 
(Krueger 2002). In patients presenting with physical symptoms comorbid depression, anxiety 
and SDs are common (for depression 50%-69% and anxiety 40%-50%) (Kroenke, Rosmalen 
2006). The total symptom count and not the specific type of symptom has also been identified 
as a strong predictor of anxiety and depression (Kroenke, Rosmalen 2006). For SDs, co-
morbidity with anxiety/depressive disorders has been reported 3 times more likely than 
expected by chance (De Waal, Arnold et al. 2004), and the prevalence of comorbid depression 
has been reported to range from 55% to 86% and anxiety disorders from 31% to 43% (Brown, 
Golding et al. 1990; Rief, Hiller et al. 1995). The most frequent comorbid SD has been said to 
be PD occurring alongside depression and anxiety disorders, in which case PD precedes 
depression/anxiety (Wittchen, Essau et al. 1993). Personality disorders according to DSM-III-
R, has also been reported in 61% of patients with SDz (Rost, Akins et al. 1992) with avoidant, 
paranoid, self-defeating and obsessive-compulsive (but not histrionic) personality disorder, 
being the most common. 
Although the literature points out that overlap between individual functional syndromes 
is extensive, data from follow-up studies concerning the amount of overlap and discreteness 
of individual disorders within the SDs category are missing. Even though there are numerous 
reports, as referred to above, confirming the high comorbidity with depression and anxiety, 
these reports are again nearly exclusively related to SDs according to lifetime MUS criteria. 
Thus co-morbidity with both depression/anxiety and functional disorders such as fibromyalgia 
and chronic fatigue are still needed to explore diagnostic distinctness. 
1.7.6 Predictors and risk factors 
Psychological distress has been found associated with MUSs (Kirmayer, Groleau et al. 2004) 
and patients reporting poor health or many (5 or more) physical symptoms to be more likely 
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to have an underlying mental disorder (Jackson, Houston et al. 2001). The likelihood of 
having a psychiatric disorder has also been shown to increase dramatically with increasing 
numbers of physical symptoms (Kroenke, Spitzer et al. 1994). In patients attending 
neurology, cardiology and gastroenterology clinics, the number of physical symptoms has 
also been found to predict outcome more accurately than health anxiety (Jackson, Fiddler et
al. 2006). Patients presenting with multiple symptom complaints have often been perceived 
by physicians as “difficult” (Lipsitt 1997; Steinmetz, Tabenkin 2001). Patients characterized 
as “difficult” have also been found to have a high degree of unmet health care expectations 
(Jackson, Kroenke 2001; Bell, Kravitz et al. 2002) and to often satisfy the criteria for MSD 
(Hahn, Kroenke et al. 1996). 
Predictors of having a stable or chronic course of SDs over a 3 ½ year period, have 
previously been described as female gender, prior substance use, and anxiety disorder (Lieb, 
Zimmermann et al. 2002). Other risk factors associated with SDs, such as childhood 
experience of illness in parents (Hotopf 2002) and prior stressful life events (Craig, Drake et
al. 1994; Aggarwal, McBeth et al. 2006), lower educational level and lower household 
income (Hiller, Rief et al. 2006) have also been identified. 
Although diverse risk factors associated with SDs have previously been identified, and 
the female gender preponderance of suffering from MUSs revealed, empirical evidence  
related to the identification of patients at risk for having a chronic course is still insufficient. 
In spite of diagnostic criteria being revised in 2000 by the DSM-IV-TR (American 
Psychiatric Association 2000), SDs as an entity are still afflicted by many difficulties; 
conceptual and nosological problems, issues of diagnostic reliability and utility, insufficient 
empirical evidence behind the SDs of today and future SDs diagnostic recommendations, lack 
of knowledge in diagnostic overlap, co-morbidity and stability, as well as course and 
prognosis, including risk factors and aetiology (Kent, Tomasson et al. 1995; Rief, Hiller et al. 
1995; Barsky, Fama et al. 1998; Simon, Gureje 1999; Lieb, Zimmermann et al. 2002; Creed, 
Barsky 2004). 
1.8 Classification dilemmas
Controversies over the existing classification of SDs are extensive and many questions have 
been raised:  
• should the category of SDs be abolished altogether in the next fifth edition, DSM-V 
(Mayou, Kirmayer et al. 2005) or should it be retained (Hiller, Rief 2005; Hiller 2006; 
Rief, Isaac 2007)?  
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• should SDs be renamed and moved to Axis III in DSM-V (Kroenke 2006; Sykes 2006) 
or moved within the next DSM-V to the “Psychological factors affecting medical 
condition” category (Fava, Fabbri et al. 2007)?  
• should a new category of SDs encompass disorders like Chronic fatigue, Fibromyalgia, 
Irritable bowel syndrome or the Functional gastrointestinal disorders (FGID) (Jones, 
Crowell et al. 2007), redefined into a category of Functional somatic syndromes (FSS) 
(Henningsen, Zipfel et al. 2007) and merged as “interface disorders” belonging to both 
the realm of mental and physical disorders (Strassnig, Stowell et al. 2006)?  
• should gynaecological symptoms, such as dyspareunia be part of a future SDs pain 
category  or not (Binik 2005; Spitzer 2005; First 2005)? 
• which symptoms should be examined and how many counted (Kroenke 2006), and 
should number of symptoms be the same for women and men? 
• should the dichotomizing of bodily symptoms into “medical” and “psychiatric” types be 
completely done away with (Sharpe, Mayou et al. 2006)?  
• should disorders of the SDs category be lumped together or differentiated (Kroenke 
2006; Henningsen, Lowe 2006) and do the assumed distinctive characteristics of SDs 
actually distinguish them from other disorders or not (Kendell, Jablenski 2003)?  
• should utilization of health care be regarded as a symptom to screen for SDs (Smith, 
Gardiner et al. 2001; Smith, Gardiner 2006) or excluded as being in effect an outcome 
measure?  
Work has already begun on the DSM-V, with its publication anticipated in 2011(2006) and 
the revision of SDs has been pointed out as highly needed (Wise, Birket-Smith 2002). 
Recommendations to resist political pressures for a change of terms, and to change 
terminology only if this has a clear clinical advantage have also been emphasized (Starcevic 
2006). Fundamental issues are the rethinking of traditional taxonomy of SDs and how to 
decipher whether the taxa are valid psychopathological syndromes or not, and if so, whether 
they are best represented by a descriptive or etiological approach, and by a categorical or 
graded/dimensional approach (Joiner, Jr., Schmidt 2002). The importance of utility (First 
2004), as well as reliability and psychosocial impairment criteria (Mayou, Kirmayer et al.
2005) should also be remembered when defining case thresholds.  
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2. The thesis 
On this background the present thesis is about SDs and their symptoms (MUSs), elucidating 
the problems concerned with lifetime symptomatology and the MUS/MES distinction, 
exploring the course, stability, overlap and comorbidity of SDs with anxiety/depression and 
musculoskeletal disorders, examining risk factors and predictors, with a focus on presenting 
prevalence of SDs according to current symptom criteria for the first time in Norway. In 
effect, a main aim has been to contribute to the ongoing debate of the future of SDs by 
attaining more knowledge and shedding light on conceptual issues, diagnostic validity and 
reliability, thus providing more empirical evidence for future recommendations.  
2.1 Aims of the thesis 
The main object of this thesis was to explore discrepancies of the existing criteria of SDs, for 
example of that between MUS and MES, lifetime and current by examining course over time, 
overlap, stability, co-morbidity and risk factors of SDs. A main aim was to present for the first 
time in Norway, occurrence of SDs according to recently suggested current criteria. A central 
object was to provide more empirical evidence to the debate of future suggested changes to 
SDs and whether SDs should be considered mental disorders or not.  
Problems that this thesis tries to answer are:  
Paper I:
• How stable are lifetime symptoms over time and is the differentiation of symptoms 
into the MES/MUS categories reliable? 
• What are the factors influencing the tendency to lose symptoms to recall? 
Paper II:
• What is the course of MUS-pain (representing SDs at the one symptom level) over 
time?  
• What are the characteristics of chronic or persistent MUS-pain sufferers who report 
recent (within the last 6 months) MUS-pain in 1990 and 2001? 
• What are the predictors of recent MUS-pain in 2001? 
39
Paper III:
• What is the extent of overlap between SDs, and can boundaries or disorder 
discreteness “zones of rarity” be identified? 
• What is the stability of SDs over time?  
• To what extent are SDs comorbid with anxiety and depression?  
• Are there differences in predictors between current SDs versus lifetime SDs criteria?  
Paper IV:
• What are the prevalence rates of current SDs in 2001?  
• What is the co-morbidity of current SDs with anxiety/depression and musculoskeletal 
disorders?  
• Do co-morbid sub-groups of current SDs differ in psychological distress? 
• What are the arguments for still regarding SDs as mental disorders? 
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3. Material and methods 
3.1 Materials 
Two general population samples from The Oslo-Lofoten study, all 18 years of age or older are 
studied in this thesis (Paper I, II, III and IV).  
Table 5. Characteristics of Papers I-IV 
Paper Subjects Selection Year N 
Response 
rate Women 
Geographical 
Area  Design 
Mean 
age 
I, II, III General 
population - 
CIDI
somatoform 
section 
interviewed  
1990-2001 
Follow-up 
Pre-
selection  
by HSCL-
25  
1990 
&
2001 
421 70% out of 
605 at 
baseline  
57.5% 44.2% (Oslo) Prospective 42.9 
(baseline) 
53.9 
(follow-
up)
IV General 
population  
- CIDI 
somatoform 
section 
interviewed   
2001 
Sample
Excluded  
- subjects 
from 1990 
interviewed 
again in 
2001 
(N=421) 
2001 1247 61% out of 
all 2049 
actually 
contacted  
50.8% 44.4% (Oslo) Cross-
sectional 
46.8 
3.2 Methods 
3.2.1 Design of the studies 
3.2.1.1 Longitudinal prospective design 
A longitudinal prospective design was utilized in Paper I, II and III, following up respondents 
who had been interviewed with the Somatoform section of the Composite International 
Interview (CIDI) in 1990. Respondents interviewed at baseline in 1990 were contacted again 
and interviewed for the second time in 2001. Respondents from 1990 who had been lost to 
follow-up due to death or other reasons were also identified. 
3.2.1.2 Cross-sectional design 
A cross-sectional design was utilized in Paper IV. New randomly selected respondents, added 
on to the old 1990 cohort, interviewed with the CIDI somatoform section for the first time 
were selected. All respondents from 1990 who had been interviewed again in 2001 (N=421) 
were excluded, reasons for the elimination are given in 3.2.2.3.  
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Figure 1. The Oslo–Lofoten study, CIDI somatoform section interviewed, 1990 and 2001 
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3.2.2 Method design 
The studies of this thesis encompass both a retrospective and prospective methodology, since 
questions about the past “have you ever had” and present “here and now” were asked in both 
1990 and 2001. Respondents in all the studies were recruited from two geographical areas, 1) 
Lofoten - representing a typical traditional ethnic Norwegian rural west coast population and 
2) Holmlia suburb, Oslo – representing a more modern Norwegian city diverse population of 
both ethnic Norwegian and immigrant origin.  
3.2.2.1 Inclusion criteria, 1990/2001 Follow-up  
Paper I, II and III:
An initial general population random sample of 5,000 individuals, 18 years of age or older 
(2,600 from Holmlia and 2,400 from Lofoten), was drawn from the National Population 
Registry administered by Statistics Norway in 1989 (see Figure 1). Since the goal was to 
obtain a high number of persons, approx. 2000 included, information letters were sent to a 
random selection of 3,656 (2,055 in Oslo, 1,601 in Lofoten) out of the initial 5,000 draw. 
Altogether, 929 persons out of 3,656 were excluded since they had moved, could not be 
located or were dead. The final number of 2,727 persons left were approached with the 
Hopkins Symptoms Checklist 25-item self-rating scale (HSCL-25), out of which 713 refused 
and 2,014 (1,009 in Oslo and 1,005 in Lofoten) consented to participate, i.e. 74% of the 
eligible 2,727 population sample. All respondents (N=405) in 1989 with HSCL-25 scores 
<1.55 as well as a random selection (N=200) of those with HSCL-25 scores ≥1.55 were 
interviewed with the CIDI somatoform section and included (N=605) in 1989/1990 (hereafter 
“baseline” or 1990 (Papers I-III)). Altogether 184 out of 605 (30%) respondents were lost to 
follow-up in 2000/2001 (hereafter “follow-up” or 2001 (Papers I-III)), leaving a total of 421 
respondents interviewed at both time points (114 or 62% of whom were women).   
3.2.2.2 Lost to 1990/2001 Follow-up  
Table 6. Respondents lost to follow-up 
Paper Subjects lost to follow-up (N=184) N Women Mean HSCL-25  
Mean age in years 
(at baseline) 
- dead 73  47.9% 1.69 68.9  
- refused 49  71.4% 1.73 35.4 
- not found again  36  69.4% 1.70 34.1 
I, II, III 
- dement or too sick to be interviewed 26  73.0% 1.77 67.5 
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Information in 2001 concerning respondent’s place of residence (moved or emmigrated) or 
date of death was retrieved from the records of the National Population Register, stored by 
Statistics Norway. Death attrition was strongly related to old age. Mean age in years when lost 
to death was 71 for women and 67 for men (Paper I). The gender distribution and HSCL-25 
scores were not significantly different between those interviewed again and those lost to 
follow-up. However, when applying the Bonferroni post hoc test, significant differences 
between those lost to follow-up and those interviewed again in 2001 were found in numbers 
of lifetime MUS and MES at baseline (Paper I). For number of lifetime MUS at baseline, a 
significant difference (P <.05) was found between those lost due to death and those lost to 
follow-up for reasons other than death, but not for those interviewed again. For number of 
MES, the difference was significant (P <.001) between those who had died and those 
interviewed again and also significant (P <.05) between lost to follow-up other than death. 
3.2.2.3 Inclusion criteria, 2001 Sample 
Paper IV:
In 2001 a new random draw of 1,000 individuals, 18 years of age or older, from the National 
Population Register by Statistics Norway, was added to the “old” original 1990 cohort (see 
Figure 1). Reasons for the drawing of a new sample were to strengthen the cohort for later 
follow-ups and to increase the number of younger individuals and immigrants. Five hundred 
persons born between 1972 and 1982 were randomly drawn in Oslo and 400 in Lofoten, in 
addition a random draw of 100 persons born as close to 1972 as possible in Lofoten. 
Altogether 94 persons were excluded because they had moved, emigrated, were too sick to 
participate, had died or had been included previously in 1990 (see Table 7). In spite of many 
attempts, contact was not established with 193 persons, leaving a sample of 713 eligible 
respondents. Due to limited resources and time restraints 188 were not contacted. Out of the 
remaining 525 persons contacted, 134 refused and 2 were excluded due to missing data on 
CIDI somatoform section, leaving 389 included. Response rate in the “new” 389 sample was 
55% (389/713) of the potentially eligible or 74% (389/525) of those actually contacted.  
From the original cohort of 2014 individuals in 1990, 511 respondents were excluded 
and 224 refused to participate, see Table 7. Due to the pre-selection by HSCL-25 score in 
1990 for CIDI interview, all follow-up respondents from 1990 who were re-interviewed with 
the CIDI somatoform section in 2001 (N=421) were excluded. Respondents missing data in 
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the CIDI somatoform section 2001 interview (N=21) were also excluded. Response rate in the 
“old” 858 sample was 49% (858/1766) of the potentially eligible and 56% (858/1524) of 
those actually contacted. The 858 respondents from the “old” cohort (interviewed with the 
CIDI somatoform section for the first time in 2001) were included alongside the 391 
respondents from the “new” sample. This left a final total of 1,247 included, with overall 
response rate 50% (1247/2479) of potentially eligible, and 61% (1247/2049) of actually 
contacted.   
Table 7. Subjects excluded in the 2001 Sample 
Old 2001 
cohort  
(N=2014) 
New 2001 
cohort  
(N=1000) 
Paper Reasons for exclusion in 2001  N N 
- dead 248 4 
- dement or too sick to be interviewed 31 3 
- too severely ill to participate 37 3 
- emigrated 36 3 
- not recovered from the Census Register 19 - 
- impossible to find  119 193 
- not contacted due to time limit - 188 
- included previously in 1990 - 5 
- did not speak Norwegian - 8 
- moved from study regions - 68 
- interviewed in 1990, interviewed again in 2001 (1990/2001 Follow-up) 421 - 
- not interviewed with CIDI somatoform section in 2001 21 2 
Refused 224 134 
IV
Total 1156  611 
Age and gender distribution of the 2001 Sample compared to that of the Norwegian 
general population of 2001 (Sandanger, Nygard et al. 2006) are given in Table 8. 
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Table 8. The Norwegian population and 2001 Sample, gender and age distribution  
The Norwegian Population 2001: The 2001 Sample: 
Women Men Women Men 
Age N % N % N % N % 
18-34 511997 29 527497 31 134 21 134 22 
35-49 480501 27 499452 29 276 44 237 39 
50-65 409312 23 416044 24 146 23 157 25 
66+ 378171 21 267652 16 77 12 86 14 
Total 1779981 100 1710645 100 633 100 614 100 
3.2.3 Samples and studies  
3.2.3.1 1990/2001 Follow-up  
Paper I, II and III:
Participating respondents (2,014; 74% of the eligible 2,727 source population) in 1989 
comprised a sample that was representative with respect to age (18–39 years 49%, 40–59 
years 28%, 60 years and above 23%) and gender (women 53%, men 47%) of the source 
population. The HSCL-25 questionnaire was used as a screen for mental health and chosen for 
its ongoing (present and last week) symptom load assessment and as a measure of 
psychological distress (Derogatis, Lipman et al. 1974; Rickels, Garcia et al. 1976; Winokur, 
Winokur et al. 1984). In 1990 all respondents with HSCL-25 cut off point <1.55 in addition to 
a random sample of those with HSCL-25 score ≥1.55 were selected for CIDI interview. All 
interviewers (both professional and lay interviewers) underwent CIDI interview training 
conducted by the study’s leading psychiatrist. 
Reasons for the choice of a longitudinal prospective design were to be able to assess the 
same respondents over an eleven year interval, making it possible to evaluate the stability of 
reported lifetime MUS and MES (Paper I), course of MUS-pain and factors associated with 
chronicity (Paper II) and overlap, co-morbidity and stability of disorders (Paper III).  
3.2.3.2 2001 Sample 
Paper IV:
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In 2001, all randomly selected respondents from the National Population Register by Statistics 
Norway who had responded to the HSCL-25 questionnaire (N=2014) were selected for CIDI 
interview (see Figure 1). All those who had responded to the CIDI somatoform section were 
included, no sub-sampling was undertaken. Even after all follow-up respondents from 1990 
interviewed again in 2001 (N=421) were excluded, the number of respondents who had been 
included in the 2001 sample was still high (N=1247).  
Reasons for the choice of the cross-sectional prevalence design were to examine 
prevalence of SDs according to new current symptom criteria as accurately as possible, by the 
updated somatoform section of the WHO-CIDI version 1.2 used in 2001. In addition the 
supplementary interview schedule and self-questionnaire developed by the Oslo-Lofoten 
study (see 3.2.4.1) had been revised in 2001, making it possible to identify risk factors and the 
use of health care more extensively, as well as examining comorbidity with musculoskeletal 
disorders (including Fibromyalgia and Chronic Fatigue, see Appendix 7). 
3.2.4 Instruments and variables 
3.2.4.1 Instruments 
The Composite International Diagnostic Interview (CIDI):
Respondents in the Oslo-Lofoten study in 1990 were interviewed with the CIDI version 1.0 
(Robins, Wing et al. 1988) and in 2001 with the computerized M-CIDI 1.1 (updated 
electronic version of WHO-CIDI version 1.2) (Wittchen, Lachner et al. 1998) in 2001. 
According to ICD-10 research criteria the diagnostic focus in 1990 was on the following 
disorders: panic disorder, generalized anxiety disorder, phobic disorder, major depression and 
dysthymia, and SDs (including dissociative disorders)) (Sandanger, Nygard et al. 1999).  
The CIDI version 1.0 somatoform algorithms in 1990 consisted of SDz (F.45.0) and PD 
(F45.4) (see Table 2). In 2001 the updated CIDI version 1.2 somatoform algorithms also 
included SDud (F45.1), HC (F45.2) and SDnos (F45.9) (see Table 2). All computerized 
somatoform diagnostic computations using the WHO-CIDI algorithms in 2001 were based on 
DSM-IV criteria, with just a simple conversion to the corresponding ICD-10 numbers. 
Due to the somatoform diagnostic assessment by the CIDI algorithms not being 
completely identical in 1990 and 2001, and therefore not comparable between the two time 
points – all SDs referred to in this thesis (Paper III and IV) had to be computed directly from 
the MUSs raw data in the somatoform section according to DSM-IV based criteria algorithms 
for both 1990 and 2001. The DSM-IV based criteria and algorithms were applied to the MUSs 
47
raw data are given in Paper III and IV. In 1990 the CIDI 1.0 Somatoform section examined 41 
symptoms (Appendix 3) and in 2001 the WHO-CIDI 1.2, 43 symptoms (Appendix 4). Since 
the question “Have you been sickly for the majority of your life?” (see item 43 in Appendix 3 
and 4) was not considered as a specific symptom per se, it was excluded from the data 
analyses in all Papers I-IV.  
The main reasons for the choice of the CIDI in the Oslo-Lofoten study had to do with its 
feasibility in population studies (Robins, Wing et al. 1988) and its previous application in 
many countries (Wittchen, Robins et al. 1991; Rubio-Stipec, Canino et al. 1993). Diagnoses 
by the CIDI had also been reported to show a high reliability (Wittchen 1994; Wittchen, 
Lachner et al. 1998) and the Cohen’s ț measurement of agreement (inter-rater reliability) for 
the somatoform section to be good (0.68) (Wittchen 1994). The CIDI somatoform section 
flow chart had also been reported to adequately screen for somatic symptoms in many 
countries (Rubio-Stipec, Canino et al. 1993). 
The Oslo-Lofoten Interview Schedule:
In 1990, the interview schedule consisted of altogether 182 items. In addition to demographic 
variables the items were wide-ranging covering many diverse topics, for example education; 
income; the experience of alcohol problems/mental illness among parents; utilization of health 
services, including mental health care; use of narcotics and medication, including sedatives 
and tranquillizers; experience of significant and traumatic life events; religious beliefs; social 
support; physical diseases, including cancer; smoking habits; coffee drinking and eating 
habits; housing, leisure time activities and hobbies; health care contact, including mental 
health care, and admission to hospital; satisfaction with the health care provided.  
In 2001 the interview schedule had been updated and improved, and altogether it 
consisted of 131 items. Several items, for example those pertaining to nutrition and housing, 
were not found sufficiently relevant to be continued in 2001. Since the 1990 schedule was 
extremely long and time consuming, items were either compressed or reduced, and updated 
also as for relevance. For example, the exploration of physical diseases which consisted of a 
22-item physical disorder list in 1989 was reduced to a 17-item disorder list in 2001, yet 
adding such disorders as Chronic Fatigue and Fibromyalgia. Even though most items were, 
for research purposes, kept identical at both time points, several items contained more detail 
in 2001, either by additional questions relating to the time frame involved or to the degree of 
severity (mild, moderate, or severe). For example, stressful life events examined by the 52-
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item Stress Life Event list, was improved in 2001 with the addition of severity for each event 
added (i.e. affected by the event; a little, somewhat, or very much).  
The Oslo-Lofoten Self-questionnaire:
In 1990, the self-questionnaire consisted altogether of 52 items. The items comprised self 
assessed health; satisfaction with life; general well-being; working ability; global opinions on 
the health services (including mental health care) provided; alcohol use and drinking habits; 
opinions on housing, neighbourhood and working conditions; experience of social support 
and social environment; and in addition included the HSCL-25 questionnaire. 
In 2001 the self-questionnaire consisted altogether of 59 items and was primarily a 
follow-up and an update of the 1990 questionnaire. Nearly all items were either identical (for 
example the HSCL-25) or improved with more detail (for example related to the time frame). 
A few questions from 1990 were found either not applicable in 2001 or too elaborate to be 
continued, for example items related to detailed health concerns/opinions applying to the local 
environment.  
3.2.4.2 Variables 
An overview of dependent variables are given in Table 9, and independent variables in Table 
10. The choice of independent variables to be explored in the regression analyses of Papers I-
IV were either based on theoretical considerations, earlier literature reports of significant 
associations or a significant bivariate correlation (Pearson’s r, P<.05) with the dependent 
variable being examined in the present study. 
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Table 9. Dependent variables included in Papers I-IV 
Paper I Paper II Paper III Paper IV 
Number of MUS-lost to recall X    
Number of MES-lost to recall X    
Recent MUS-pain in 2001  X   
“Lifetime” SDs in 2001   X  
“Current” SDs in 2001   X  
Severe current SDs    X 
Anxiety disorders    X 
Depressive disorders    X 
Musculoskeletal disorders    X 
Health care utilization (last 12 months):     
- Mental health care    X 
- Admission to hospital     X 
- Consultation with general practitioner/hospital physician    X 
Use of medication:     
- Analgesics (daily or weekly)    X 
- Benzodiazepines (daily or weekly)    X 
- Antidepressants (last 12 months)    X 
Table 10. Independent variables included in Papers I-IV 
 Paper I Paper II Paper III Paper IV 
Gender X X X X 
Age X X X X 
Education X X   
Residential area, Oslo / Lofoten  X  X 
Experience of alcohol problems/mental illness among parents  X  X 
Living alone  X   
HSCL-25 score X    
HSCL-25 anxiety sub-score    X 
HSCL-25 depression sub-score    X 
Stressful life events, 52-item scale  X  X 
Working ability score    X 
Satisfaction with life score    X 
Self assessed health score    X 
MUSs X   X 
MESs X   X 
Recent MUS-pain  X   
Physical disorders, 15-item list X X X  
Physical disorders, 13-item list    X 
Musculoskeletal disorders, 4-item list    X 
Depression  X X  
Anxiety  X X  
Lifetime SDs   X  
Current SDs   X  
Use of analgesics (daily or weekly)    X 
Use of antidepressants (last 12 months)    X 
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3.2.4.3 Description of variables 
For research purposes variables examined in the 1990/2001 Follow-up (Paper I, II and III) had 
to be directly comparable, at both time points. Variables explored from the comprehensive 
Oslo-Lofoten Interview Schedule or the Self-Questionnaire were chosen according to this 
requirement in Paper I, II and III and if necessary adapted accordingly, as described below. In 
Paper IV all variables from the improved Oslo-Lofoten Interview Schedule 2001 or Self-
Questionnaire 2001, were chosen in order to give more detailed information, for example the 
use of antidepressants during the last year (asked in 2001 but not in 1990). 
Sociodemographic variables:
In all regression analyses (Papers I-IV) age and education in years was divided into 10-year 
groups (decades). Results in Papers I-III were also presented according to the following age 
groups: <35 years, 35 to 55 years, >55 years (Paper I), 18 to 28 years, 29 to 44 years, 45 to 60 
years, >61 years (Paper II) and <50 years, >50 years (Paper III).  
In Paper IV prevalence rates of current SDs was stratified by gender and age, into age 
groups: 18 to 34 years, 35 to 49 years, 50 to 65 years, >65 years. Residential living area was 
in all papers treated according to the dichotomy Oslo/Lofoten according to the address by the 
National Population Register. Other dichotomous socio-demographic variables were 
experience of alcohol problems/mental illness among parents, and living alone.  
Somatoform, anxiety and depression disorders:
All disorders in all papers were dichotomous, yes/no. All SDs of Paper III and IV were 
computed from the MUSs raw data according to disorders described in the SDs category of 
DSM-IV-R (American Psychiatric Association 2000) including the MSD of DSM-IV-PC 
(American Psychiatric Association 1995) and MSD criteria described by Kroenke et al. 
(Kroenke, Spitzer et al. 1997). The diagnostic criteria (number of MUS, duration and onset) in 
the computation of SDs from the MUS raw data for Paper III are given in the Table 1 of Paper 
III.  In Paper IV the diagnostic criteria for MSD and SDnos, and the groups “current SD” and 
“severe current SDs” with impairment added, are given in Appendix B of Paper IV.  
Due to differences in the physical symptom lists of the somatoform section of CIDI 
version 1.0 (Appendix 3) and WHO-CIDI version 1.2 (Appendix 4), only 38 physical 
symptoms, identical at both time points in 1990 and 2001, were utilized in the data analyses 
pertaining to Paper I, II and III. In Paper IV the feeling item 43 “often felt sickly” was omitted 
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and the remaining symptoms (42-items) used diagnostic computation according to the criteria 
of DSM-IV-R.   
Anxiety and depressive disorders examined were those computed by the CIDI 
program’s computerized algorithms according to ICD-10. Depressive disorders were 
dichotomized into yes/no, and yes consisted of those recorded from F31.3 to F34.1, present 
during the last 12 months. Likewise, anxiety disorders were dichotomized (yes/no) by ICD-
10, and yes consisted of those recorded from F40.0 to F41.8, present during the last 12 
months.  
The Hopkins Symptoms Checklist 25-item self-rating scale  (HSCL-25):
The HSCL-25 score (Appendix 5) was treated as a continuous variable in all analyses. In 
Paper I, the HSCL-25 was chosen as a measure of current psychological distress (Derogatis, 
Lipman et al. 1974; Rickels, Garcia et al. 1976; Winokur, Winokur et al. 1984), not least 
since it has been recognized as a sensitive case-finder of anxiety and depression (Sandanger, 
Moum et al. 1999; Frojdh, Hakansson et al. 2004). The HSCL-25 score was not chosen as an 
independent variable in the regression analyses of Paper II and III since the ICD-10 disorder 
categories anxiety and depression (see paragraph above) were chosen here instead. In Paper 
IV the HSCL-25 anxiety and depression subscales (given in Appendix 5) were chosen as 
independent variables rather than the total HSCL-25 score, since information specific to each 
of the dimensions was the focus of interest.  
Physical disorders:
Since physical disorders in the Oslo-Lofoten Interview Schedule of 1990  and 2001 were 
categorized slightly differently at the two time points (see 3.2.3.3 Instruments), the disorders 
were pooled into a 15-item Physical disorder list (see Appendix 6) in order to be directly 
comparable for the analyses in Paper I, II and III.  
In Paper IV, the physical disorders examined were divided into two groups, i) a 4-item 
musculoskeletal disorder list and ii) a 13-item physical disorder list (see Appendix 7). Only 
disorders recorded as having a moderate to severe impact were analyzed. The number of 
disorders was employed as continuous variables in the logistic regression analyses of Paper 
IV. The musculoskeletal disorders were also dichotomized into yes/no, in order to examine 
co-morbidity and to identify sub-groups of severe current SDs (Paper IV).  
Stressful Life Events Scale:
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Stressful life events were examined according to the 52-item Stressful Life Event Scale (see 
Appendix 8) by the Oslo-Lofoten Interview Schedule in 1990 and 2001. The 52-items scale 
was developed for the Oslo-Loften study, based on a reduced version of Paykel and Mangen’s 
63-item schedule “Interview for Recent Life Events” (Paykel, Mangen 1980; Paykel 1983). 
The life events included events of both an acute and a more enduring chronic strain nature 
(Avison, Turner 1988) and encompassed nine areas:  work, education, finance, health, 
bereavement, migration, courtship, legal, family and social relationships. Only events 
experienced during the last year were included (both in Paper II and IV) and in 2001, only 
events having a moderate to severe impact. In 1990 (Paper II), all events were included, since 
severity of impact was not measured at this time point.  
Self assessed health score: 
Assessment of global health by the Oslo-Lofoten self-questionnaire 2001 was measured by 
requesting the respondent to assess, his/her global health at present on a scale from (1) very 
bad to (4) very good (Paper IV).  
Satisfaction with life score:
Satisfaction with life by the Oslo-Lofoten self-questionnaire 2001 was measured by 
requesting the respondent to assess, his/her general life satisfaction at present on a Cantril 
ladder scale from (1) worst life situation to (10) best life situation  (Paper IV). 
Working ability score:
Working ability by the Oslo-Lofoten self-questionnaire 2001 was measured by requesting the 
respondent to assess, his/her working ability at present on a scale from (1) very reduced to (6) 
not reduced at all (Paper IV). 
Health care utilization and use of medication:
Health care utilization, both mental health care and general health services, by the Oslo-
Lofoten self-questionnaire 2001 was measured by having been to inpatient or outpatient 
treatment and/or consultation during the last 12 months. Use of medication, such as analgesics 
was reported as daily or weekly, and the use of antidepressants during the last year (Paper 
IV).
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3.3 Ethics 
The Oslo–Lofoten study, 1990 and 2001, was approved by the Norwegian Data Inspectorate 
and the Norwegian Social Science Data Services. The study was conducted in accordance 
with the guidelines of the Helsinki II declaration. Informed consent was obtained from all 
participants at both time points.  
3.4 Statistical analysis 
Paired-samples t-tests were used to examine mean changes from baseline to follow-up for 
continuous variables, for example numbers of symptoms (Paper I), numbers of physical 
diseases and stressful life events (Paper II). Degree of statistical association between pairs of 
variables was examined by the Pearson’s r (Phi for dichotomous variables) product moment 
correlation coefficient and Spearman’s rho (ρ) non-parametric test of correlation (Paper I). 
Associations between pairs of nominal variables were measured by Kendall’s tau-b (Paper I), 
Chi-square (Ȥ2) and Cohen’s kappa (ț) (Paper II, III), and by the tetrachoric correlation 
coefficient (r*) (Paper III). The reason for the choice of r* in Paper III was that ț is influenced 
by trait prevalence (distribution or base-rates) while r* allows for the assumption that 
(liability for) the underlying trait is continuous and normally distributed.  
In Paper IV reliability of the HSCL-25 scores based on internal consistency was 
estimated by Cronbach’s alpha. The Cohen’s d was also used to calculate effect sizes on total 
HSCL-25 score and HSCL-25 anxiety and depression sub-scores, between the “severe current 
SDs only” subclass and other subclasses (Table 4 of Paper IV). 
The Bonferroni post-hoc test was applied to compare those interviewed again in 2001 
and those lost to follow-up. Multiple linear regression analyses were conducted in Paper I and 
IV and logistic regression analyses in Paper II, III and IV. Reasons for the choice of 
independent predictor variables were either i) significant bivariate correlation by Pearson’s r 
(P<.05) with the dependent variable ii) a clinical relevance pertaining to factors often 
associated with the dependent variable or iii) factors previously described in the literature as 
being associated with the dependent variable . Two-way statistical interactions between all 
pairs of independent variables entered in the regression analyses were tested separately, one 
pair at a time. Logistic regression analyses were also used to test gender and age group 
prevalence rate differences in Paper III, with the diagnosis or diagnostic group as the 
dependent variable, and age and gender as independent variables.  
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Stability of diagnoses (Paper III) was measured by prospective and retrospective 
consistency, i.e. prospective consistency: the percent of respondents with diagnoses in 1990 
having the same diagnoses again in 2001, and retrospective consistency: the percent of 
respondents with diagnoses in 2001 having had the same diagnoses in 1990. The likelihood of 
having the same diagnoses again in 2001 was also estimated by calculating the Odds Ratio 
(OR).
Six month prevalence rates (%) and 95% confidence intervals (CI) of current SDs 
(individual diagnoses and groups), according to gender and age, were computed by one-way 
analyses of variance (Paper IV).  
In all Papers I-IV the level of significance (P-value) was set at P <.05 and the statistical 
significance reported as either P <.05, P <.01, P <.001, or non-significant (NS). Statistical 
data analysis was performed using the Statistical Package for the Social Sciences (SPSS, Inc., 
Chicago, IL, USA) versions 12.0 and 14.0 for Windows. 
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4. Summary of papers and results  
4.1 Paper I 
Leiknes KA, Finset A, Moum T, Sandanger I. 
Methodological issues concerning lifetime medically unexplained and medically 
explained symptoms of the Composite International Diagnostic Interview: a prospective 
11-year follow-up study. J Psychosom Res 2006;61:169–79 
This paper presents results from the Oslo-Lofoten study at baseline (1990) and at follow-up 
(2001). The sample comprised 605 respondents interviewed with the CIDI somatoform 
section at baseline and 421 (242 (57.5%) women and 179 (42.5%) men), interviewed again in 
2001. The response rate was 69.6% (421/605) and among those lost to follow-up, 73 (39.7%) 
were lost due to death. 
The aims of this paper were 
• to elucidate methodological problems arising when examining lifetime symptom data 
by exploring the accuracy of recall of MUSs and MESs, for those interviewed by the 
CIDI, somatoform section in 1990 and 2001.  
• to find predictors of “symptoms lost”, i.e. symptoms that had been reported at baseline 
but were not recalled at follow-up  
A wide range of individual lifetime symptoms, from 22 to100%, were lost to recall at follow-
up. This indicated a large degree of measurement error, mainly due to faulty recall over time. 
The recall of lifetime symptoms when grouped into broader categories of number of 
symptoms was somewhat better than for individual symptoms (approx. 50% recall for 1 to 3 
symptoms). Gender and age emerged as significant (P<.01) markers for MUSs-lost, and a 
decrease in physical morbidity for MESs-lost. Men tended to forget more symptoms than 
women. Younger respondents with high levels of baseline MUSs tended to remember slightly 
better at follow-up. The large degree of recall variability and transition of MUS to MES and 
visa versa over time, cast doubt on the credibility of the medically unexplained and explained 
distinction. Lifetime symptom data elicited in community surveys by diagnostic instruments 
such as the CIDI should be viewed with caution.  
Methodological errors weakening the data credibility could lead to false impressions of 
true change over time. The distinction between medically unexplained and medically 
explained physical symptoms seems difficult to maintain.  
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4.2 Paper II 
Leiknes KA, Finset A, Moum T, Sandanger I.  
Course and predictors of medically unexplained pain symptoms in the general 
population. J Psychosom Res 2007;62:119-28. 
This paper presents results from the Oslo-Lofoten study at baseline (1990) and at follow-up 
(2001) pertaining to clinically significant and recent medically unexplained pain symptoms 
(MUS-pain). Recent symptoms are defined as those present within the last six months 
preceding the CIDI interview at baseline and at follow-up. The sample comprised 605 
respondents interviewed with the CIDI somatoform section at baseline and 421 (242 (57.5%) 
women and 179 (42.5%) men), interviewed again in 2001. 
The aims of this paper were  
• to explore the course of MUS-pain (a SDs disorder at the one-symptom level) over 
time and to identify “persistent” or chronic cases (i.e. recent MUS-pain in both 1990 
and 2001) 
• to find predictors of recent MUS-pain in 2001, related to sociodemographic 
background, level of and/or change in physical morbidity, depression and anxiety, and 
number of stressful life events experienced within the last year 
A small “stable” group of recent MUS-pain sufferers (8% out of all reinterviewed and 33.6% 
out of those with recent MUS-pain at baseline) was evident. Almost all were women. Female 
gender was a significant (P<.05) predictor, giving a twofold risk compared with men of 
having recent MUS-pain in 2001. In addition only co-morbid depression and not the 
occurrence of prior recent MUS-pain at baseline, remained a significant (P<.05) predictor, 
increasing the likelihood of having recent MUS-pain at follow-up threefold.   
The prognosis of MUS-pain is relatively good, except for a small group (mainly women) 
prone to chronicity. Clinicians should examine for depression when confronted with MUS-
pain patients and be aware of the increased twofold risk for women compared with men for 
persistent MUS-pain over a long time. 
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4.3 Paper III 
Leiknes KA, Finset A, Moum T, Sandanger I.  
Overlap, comorbidity and stability of somatoform disorders, and the use of current 
versus lifetime criteria. Psychosomatics [in press, accepted 2006]. 
This paper presents results from the Oslo-Lofoten study at baseline (1990) and at follow-up 
(2001) pertaining to diagnoses of SDs, and the use of current versus lifetime criteria. The 
sample comprised 421 respondents (242 (57.5%) women and 179 (42.5%) men) interviewed 
with the CIDI somatoform section in 1990 and again in 2001. Seven disorders within the SDs 
category were examined; SDz, SDud, HC, PD, Abridged somatoform disorder (SSI-3/5), 
SDnos and MSD. Disorders were pooled into lifetime (Sdz, SDud, HC, PD) and current 
(SDnos and MSD) SDs.  
The aims of this paper were  
• to examine the extent of overlap of individual SDs, the comorbidity of SDs with 
anxiety and depression and the stability of SDs over time  
• to find predictors of pooled “lifetime SDs” and “current SDs” at follow-up 
Overlap for many individual SDs, was very high >90% with r* close to 1.0. Clear distinctions 
between individual disorders were not possible to find, except for a slight distinction being 
revealed when the SDs were pooled into “current SDs” and “lifetime” SDs according to the 
recency of the underlying MUSs criteria. Comorbidity by OR ranged from 2.9 to 5.1 for 
depression and from 2.0 to 2.5 for anxiety. Comorbidity was somewhat more pronounced for 
current SDs compared to lifetime SDs, and current SDs were 4 times more likely to occur 
among depressed respondents. For current SDs, diagnostic stability by retrospective 
consistency was 42% compared to only 33% for lifetime SDs. The highest estimate of 
agreement by kappa occurred for current SDs and must be considered fair (ț =0.214, P<.001).
Among those individuals with a SD at baseline, 54% to 67% fulfilled the criteria of any SD at 
follow-up. Women <50 years of age with SD at baseline tended to show a stable (chronic) 
course over time. 
Prior depression and physical disease were risk factors for current SDs, whereas only 
prior anxiety was a significant predictor for lifetime SDs. Clinical attention should be focused 
on young women, who are at risk for having debilitating symptoms over a long time. SDs 
should be merged and future criteria should be based on current symptoms. 
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4.4 Paper IV 
Leiknes KA, Finset A, Moum T, Sandanger I.  
Current somatoform disorders in Norway: prevalence, risk factors and co-morbidity 
with anxiety, depression and musculoskeletal disorders. [submitted]. 
This paper presents results from the Oslo-Lofoten cross-sectional survey in 2001. 
Respondents were interviewed with the updated computerized CIDI (electronic DIA-X/WHO-
CIDI version 1.2) (Wittchen, Lachner et al. 1998). In order to eliminate selection bias 
connected with the CIDI interview sampling in 1990, all respondents from 1990 who were 
interviewed again in 2001 (N=421) were excluded, leaving a total of 1,247 respondents in the 
subsequent data analyses. Altogether 633 out of 1,247 (50.8%) were women and 554 out of 
1,247 (44.4%) lived in Oslo.  
The aims of the article were: 
• to investigate the prevalence of current SDs in Norway  
• to examine whether current SDs should be regarded as mental or physical conditions by  
i) inspecting risk factors of severe current SDs, anxiety/depression and musculoskeletal 
disorders, and ii) assessing psychological distress, utilization of health care and 
medication in co-morbid subclasses of severe current SDs. 
The overall pooled prevalence rate for severe current SDs (MSD and SDnos pooled, 
with psychosocial impairment applied) was 10%. Prevalence rates were generally twice as 
high for women. The main risk factor associated with severe current SDs was anxiety. Co-
morbidity of severe current SDs with anxiety/depression and/or musculoskeletal disorders 
was 69%. Psychological distress in the only severe current SDs subclass (without co-
morbidity) was significantly higher (P <.05) than among respondents without disorders. 
Mental healthcare utilization among those with current SDs depended on co-morbid 
anxiety/depression, not on the SD diagnosis alone.  
Co-morbid symptoms of anxiety/depression rather than medically unexplained 
symptoms per se, should qualify the patient for a psychiatric diagnosis. 
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5. Discussion 
This thesis covers the examination of physical symptoms and SDs by the CIDI in two 
epidemiological studies, i) a follow-up study (1990/2001 Follow-up, Papers I-III) and ii) a 
cross-sectional study (2001 Sample, Paper IV). Various sources of error that may be present 
in the studies and possibly have influenced the data will be discussed in the following 
sections.  
5.1 Methodological issues 
Methodological issues of this thesis will be considered from the two main forms of error 
(Rothman 2002), first i) systematic error, referred to as bias and secondly ii) random error.  
5.1.1 Systematic error (bias) 
Bias relevant to the studies of this thesis will be discussed in three main areas, i) selection 
bias, ii) information bias and iii) confounding bias.  
5.1.1.1 Selection bias 
Selection bias is the error arising from procedures used for finding and including respondents 
into the two samples of this thesis, i) 1990/2001 Follow-up  and ii) 2001 Sample, and from 
other factors influencing study participation. Generally the question of selection bias has to do 
with sample representativity and the possibility of drawing valid inferences regarding the 
source population.  
The source population for both these samples were inhabitants living in two different 
geographical areas in Norway, i) the northern west coast Lofoten region and ii) the Holmlia 
suburb in Oslo. Proportion respondents from Lofoten in the 1990/2001 Follow-up (Paper I-
III) were 55.8% and in the 2001 sample (Paper IV) 55.6%. One reason for the slightly better 
recruitment from Lofoten might be a better thoroughness among the Lofoten interviewers. 
Another reason could be that Lofoten community traditions might also have facilitated the 
finding and contacting of respondents a second time. Compared to Holmlia, Oslo, where 
community traditions are still young and perhaps still not so established, Lofoten has been 
influenced by a coastal fishing industry over many generations.  
All individuals were randomly selected from the National Population Register, by 
Statistics Norway, and given that all resident Norwegian citizens are in fact included in the 
register - selection bias arising from self-selection were avoided, beyond that arising from a 
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refusal to participate in the study. However, some factors influencing the study samples in the 
direction of having a better or worse health than the source population must be taken into 
account. Since all respondents that the investigators classified as demented or physically too 
ill to undergo an interview were excluded, this may have resulted in the 1990/2001 Follow-up 
(Paper I, II and III) and 2001 Sample (Paper IV) being in better health than the source 
population. Additionally immigrant respondents who did not speak Norwegian were 
excluded, resulting in a very low proportion of immigrant respondents.  
Although supported and funded by several sources, the Oslo-Lofoten study was similar 
to other long term cohort studies in being restricted by a limited budget. Not only did limits in 
resources and time influence the training of lay interviewers, but also the number of 
interviews it was possible to undertake. A clear example of this is the pre-selection of 
respondents by the HSCL-25 score for further CIDI interviewing, in 1990. Since the HSCL-
25 yields a significantly higher proportion of women than men with scores ≥1.55 (Sandanger 
1993), this necessarily caused the baseline CIDI sample to be gender biased and “sicker”, i.e. 
having a higher proportion with psychological distress and a female preponderance (57.5% 
women in the 1990/2001 Follow-up) than the general source population.  
On the other hand since most diseases affect only a small proportion of the population, 
thus requiring a very large number of respondents to be investigated in order to give reliable 
estimates of caseness, it can also be argued that the pre-selection by HSCL-25 served as an 
efficient  and resource reducing case discriminator (Sandanger, Moum et al. 1998; Sandanger, 
Moum et al. 1999). In previous prevalence rate reports by the Oslo-Lofoten study from the 
1990 data, the use of probability weights correcting for the differential representation of the 
sample is extensively described (Sandanger, Nygard et al. 1999). 
In order to eliminate all pre-selection bias by the HSCL-25 in the 2001 Sample (Paper 
IV), respondents interviewed again from 1990 (N=421) were excluded. Even after excluding 
the 421 follow-up respondents, the 2001 Sample was still large (1,247 respondents included), 
and a large sample size in itself contributes to reducing error. 
When applying the Bonferroni post hoc test on groups lost to follow-up, significant 
differences were found in number of lifetime MUS and MES at baseline (Paper I). For 
number of MES (but not for number of MUS) the difference was also significant (P<.05)
between those who were interviewed again and those lost to follow-up other than death (see 
3.2.2.2). A possible explanation for this could be that those lost to follow-up for reasons other 
than death were physically “sicker” and less able to participate.  
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Other reasons for non-response can only be conjectured. For example, when the 
respondent is initially contacted and the interviewer explains the nature and procedure of 
interview, including that interviewing could take about two three hours of their spare time, 
either during the day or evening, which ever the most convenient, this clearly appears to be 
quite lengthy. In our modern time jam, respondents might also have considered the procedure 
far too time-consuming, as well as feeling uncomfortable with the person to person interview 
situation and the disclosure of personal information.   
All procedures aiming at reducing the amount of systematic error, secure not only 
precision in measurement and estimation, but also strengthen the study’s internal and external 
validity (generalizability). In other words, the possibility of being able to draw inference to 
the source population (internal validity) and also to those outside the population 
(generalizability) is thereby created. Compared to the Norwegian population (see Table 8) the 
overall gender distribution was the same (51 %) in the 2001 Sample. However, as for the age 
groups some over representation in the 2001 Sample is found for the middle age groups (35 – 
49 years) and some under representation in the highest (66 years and above) for both genders, 
which must be taken into account when considering the external validity (generalizability) of 
the results in Paper IV. 
5.1.1.2 Information bias 
Information bias is the error stemming from flawed information being collected about the 
study or from the study subjects. All information collected in studies based on self-report, 
could be affected by information bias, also referred to as misclassification. For example the 
answers given might be affected by “socially desirable responding” or “yea-saying”, giving 
rise to answers being too much of the kind or too little, resulting in faulty or skewed data. 
Depending on the mechanism of misclassification, misclassification is often referred to as 
differential or non-differential. If the the error is correlated with or depends on the value of 
other variables then the misclassification is differential but if the error is not correlated with or 
not dependent on the value of other variables, the misclassification is non-differential.
Recall bias is a common form of information bias and differential misclassification. The 
problems related to faulty recall of lifetime MUS and MES are extensively dealt with in Paper 
I. Many respondents had completely forgotten previous recorded symptoms. The interchange 
of the MUS and MES categories over time also revealed not only a large degree of symptom 
variability but also a large degree of misclassification.  
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All interviewers in the Oslo-Lofoten study, both lay interviewers and the study’s 
participating physicians, underwent CIDI interview training, but even doctors have been 
found to err when diagnosing symptoms as MES and not MUS when the consultation 
interaction is perceived as negative (Nimnuan, Hotopf et al. 2000). Although the CIDI has 
been used by many (Rubio-Stipec, Canino et al. 1993) and is a well validated diagnostic 
instrument (Wittchen 1994; Wittchen, Lachner et al. 1998), probing extensively to find out if 
the symptom can be accounted for by a reasonable or plausible cause, i.e. either by a physical 
disease or substance/alcohol abuse, or by what the doctor has said, and accordingly classified 
as MES, a large degree of misclassification of symptoms can still arise.  
A limitation of the CIDI could lie in its use of lay interviewers, a factor which might 
have affected the temporal instability of symptoms over time. For a lay interviewer various 
medical terms used by the patient or referred to as what the doctor had said, for example 
lumbago or fibromyalgia, could easily lead to an underestimation of MUS. For example, 
clinically significant back pain for men was very rarly recorded as medically unexplained 
(Paper I). A reason for this could be that all mention of lumbago was recorded as MES-back 
pain when some rightly should have been classified as MUS-back pain, a misclassification 
directly affecting the occurrence of PD and also other SDs to be lower. An example of the 
opposite, i.e. symptoms being wrongly classified as MUS when they apparently should have 
be classified as MES, seem to be those related to the female reproductive organs, such as 
excessive menstrual bleeding and irregular menstruation. A reason for this could be the 
unclear communication between respondent and interviewer, but it could also be a sign of 
lack in gynaecological knowledge. Thus the complexity of the CIDI probe questions in itself 
leading to difficulties in answering might have resulted in some response bias (Knauper, 
Wittchen 1994). Yet another reason for the overlap of the MUS/MES categories could be that 
both physical and psychiatric causes actually contribute to the symptom (Kroenke, Lucas et
al. 1992). However, since all diagnostic computation of SDs in DSM-IV and ICD-10 is based 
on the occurrence of clinically significant MUS, misclassification of MUS is an error which 
must be taken into account. Most likely the error has resulted in symptoms being more often 
registered as explained, thereby leading to an underestimation of SDs prevalence rates based 
on these symptoms, in Paper II, III, IV. 
In spite of no obvious outliers being found among our interviewers and earlier reports of 
the CIDI showing a good inter-rater reliability (Wittchen 1994; Von Korff, Ustun 1995) the 
validity of the classification of a symptom as MES and MUS could still be quite low. 
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5.1.1.3 Confounding bias 
Confounding is a statistical concept referring to the confusion or mixing of effects. 
Confounding bias is present when the apparent effect on one’s outcome measure from a 
putative cause (exposure) is due to a common underlying cause, the confounder. There are 
two main methods to prevent erroneous conclusions due to confounding; one is 
randomization and another restriction. Restriction, i.e. the selecting of homogenous subjects 
(for example same age, same sex, same genotype) to the study, as undertaken in experimental 
animal laboratory studies, the effect of which prevents confounding, increases the study 
validity, enhancing the ability to make scientific inference. This is a strategy that cannot 
easily be used in epidemiological surveys, and it has not been employed in the papers of this 
thesis. However, statistical controls in many cases may be attained by stratifying one’s data 
according to levels at the suspected confounding variable. Randomization or random 
assignment of study subjects to experimental groups is also not used in the studies of this 
thesis, thus leaving only the method of statistically controlling for possible confounding 
effects in the data analysis. The statistical control for possible confounding effects is 
undertaken in all regression analyses of papers I-IV and described in each paper accordingly.  
Generally a confounder must be associated with both the outcome (disorder/disease) and 
exposure under examination, and fulfil three criteria; i) be a risk factor for the disorder/disease 
ii) be associated with the exposure under examination in the source population and iii) not be 
affected by (caused by) the exposure or disease (i.e. it should not be an intervening variable 
between the exposure of interest and the outcome). For example in Paper I, a model for 
symptoms lost to recall and possible confounding effects are given (Paper I, Fig. 3). When 
statistically controlling for number of MUS at baseline, men tended to lose more symptoms, 
i.e. forget more than women. For respondents reporting high levels of MUS at baseline the 
propensity to lose more symptoms also increased with increasing age. Confounders 
influencing the outcome of symptoms lost to recall could be physical morbidity and 
psychological distress.  
5.1.2 Random error (precision) and statistical analyses 
Random error is the variability in the data arising from hidden (unknown) causes that are 
statistically unrelated both to the outcome and the independent variables investigated. 
Random error can also give rise to misclassification. Precision in measurement and estimation 
corresponds to the lack of random error. Precision can be affected by the study size, and the 
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negative effects of random error can be diminished by a large sample size, most importantly 
by reducing the risk of Type-II errors. The cross-sectional sample of 1,247 respondents (2001 
Sample) interviewed with the CIDI somatoform section is large and even the follow-up study 
size of 421 persons (1990/2001 Follow-up) interviewed in 1990 and 11 years later, is quite 
considerable. The inevitable attenuation of correlations between variables as a result of 
random errors thus could be counteracted and the risk of Type-II errors reduced. Reducing 
random error by creating additive summary scales with sufficient internal consistency was 
done in the case of the HSCL (in Paper IV Cronbach’s alpha for total HSCL-25 score 0.91, 
HSCL-25 anxiety sub-score 0.78, and HSCL-25 depression sub-score 0.88).  
5.1.3 Study designs  
5.1.3.1 Longitudinal prospective  
Strengths of the 1990/2001 Follow-up and its longitudinal prospective study design are the 
possibility of studying course over time. The general population sample examined in this 
thesis, from baseline 1990 to follow-up 2001, is exceptional with respect to the long 11 year 
time span (Paper I, II, III). Two sets of data on the same individuals in 1990 and 2001 made 
the examination of course over time, assessment of risk factors influencing prognoses and the 
identification of predictors possible. To the best of my knowledge no other study in Norway, 
nor any other recent international study has examined the phenomena of MUS and their 
associated SDs syndromes over such a long time interval. In this respect the results presented 
in this thesis are unique. 
The finding again of respondents in 2001 interviewed before in 1990 was achieved with 
diligence and the final response rate (70%) was high, ensuring validity of the 1990/2001 
Follow-up sample (Paper I, II and III). However, some bias associated with the non-response 
(other than death) being in poorer health at baseline must be taken into account, an aspect 
which might have caused the prevalence of disorders among respondents followed up to be 
rather low.  
5.1.3.1 Cross-sectional  
Strengths of the 2001 Sample study lie in the random general population selection from two 
geographical areas in Norway, ensuring a sample largely representative of the source 
population, and thereby allowing for valid inferences. A further strength in the 2001 study 
was the revised Oslo-Lofoten Interview Schedule and Self-questionnaire, containing more 
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specific updated questions of for example musculoskeletal disorders and use of medication 
(anti-depressives). In addition the WHO-CIDI version 1.2 also contained a revised 
somatoform section, with a larger number of symptoms examined than the previous CIDI 
version 1.0 utilized in the 1990 baseline survey. The use of the computerized CIDI interview 
in 2001 allowed direct data entry and minimized errors arising from incorrect data entry.   
However, a limitation of the cross-sectional or prevalence study design is its descriptive 
nature. Associations and risk factors found in Paper IV are therefore descriptive in character 
and not so much explanatory.   
5.2 Empirical issues 
Empirical issues dealt with in the studies of medically unexplained symptoms and their 
related SDs (Paper I-IV) of this thesis are many, difficulties of classification and lifetime 
versus current symptom criteria, prevalence, diagnostic overlap and comorbidity, course over 
time and risk factors.  
5.2.1 Diagnostic difficulties, diagnostic validity, reliability and utility 
Criterion sets and classification of mental disorders have largely been put together on the 
basis of consensus and expert opinion (Beauchaine, Beach 2006). The DSM as a whole is also 
based on a descriptive and pragmatic foundation rather than an empirical foundation or 
theories about pathogenesis (Follette, Houts 1996; First 2005). By the application of criterion 
sets and development of structured interviews, the diagnostic reliability of psychiatric 
disorders, including SDs, has been very much improved (Beauchaine, Beach 2006), even 
though many empirical questions still remain. Whether SDs really are sufficiently validated to 
defend them being treated as well-founded “taxa” in psychopathology and thus belonging to 
the future DSM-V, is the matter in question. 
Doubt about the reliability and validity of the MUS/MES differentiation and the MUS 
category on which the disorders of the SD category are based, is raised in this thesis (Paper I). 
Although the said dichotomy might be useful in some respects, the results of Paper I reveal 
that the distinction between explained and unexplained is very unreliable, affected to a large 
degree by recall bias. Nevertheless, future recommendations, for example regarding the PSD, 
are still based on assessing not fully explainable symptoms according to a 15-item symptom 
list (see Table 3 and Appendix 2).  
Some of the main issues of diagnostic validity addressed in this thesis (Papers II-IV) are 
those of the Feighner Phases  4, follow-up study/predictable course (Paper I, II and III) and 
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Feighner Phase 3, delimitation from other disorders (Paper III and IV) (for Feighner Phases, 
see Table 1). Antecedent validators (predictors and risk factors) are also addressed by the 
regression analyses in Papers I-IV and predictive validators concerning diagnostic consistency 
over time, relapse and recovery (Paper II and III). The issues of course, relapse and recovery 
of SDs, at the one symptom level (by current MUS-pain), are addressed in Paper II. The 
extensive diagnostic overlap of SDs subtypes (SDud, HC, PD, SSI-3/5, SDnos and MSD) 
with the only possible differentiation being between pooled “current SDs” and “lifetime SDs” 
is dealt with in Paper III, as well as the superior consistency (stability) of pooled “current 
SDs” compared to “lifetime SDs”. Although the use of symptoms lists to count ensures higher 
diagnostic reliability, the question of utility remains. Viewed from a primary care perspective, 
the more complex the amount and type of symptoms for which it is necessary to examine, 
including the combination of symptom types to fulfil the diagnostic criteria (as in SDz), the 
lower the diagnostic utility seems to be.   
5.2.2 Symptom lists and symptom counting   
The quandary associated with unexplained symptom counting and the threshold required for 
diagnosing a disorder, either being very low (at the one symptom level) or very high (at 6 for 
ICD-10 and 8 for DSM-IV) is reflected in Paper II and IV. In spite of DSM-III-R introducing 
the new disorder SDud due to the symptom count dilemma of SDz, this does not seem to have 
solved the problem. In order to comply with the DSM-IV and ICD-10 diagnostic criteria, the 
symptom screening in the older CIDI 1.0 Somatoform section 41-item symptom list (see 
Appendix 3) in the WHO-CIDI 1.2 was changed to a 43-item symptom list (see Appendix 4). 
However, nearly all symptoms in the CIDI somatoform section lists are clearly taken from the 
original 59-item symptom list of Hysteria (Feighner, Robins et al. 1972) based on the work by 
Perley and Guze, in 1962 (Perley, Guze 1962) (see Appendix 1). In this respect the symptom 
lists used today appear very much unchanged (see Table 4), and symptoms seem to have just 
“survived” when they are in fact out-dated. An example of this is also seen in the symptom 
“feeling sickly” - since it was not regarded as a symptom per se it was excluded, in all Papers 
I-IV. Other symptoms, such as menstrual irregularities, excessive menstrual bleeding and 
vomiting during the whole pregnancy, can also very much be questioned as to their legitimacy 
for being on today’s symptom lists used for diagnosing SDs. Similar to the exclusion of 
amenorrhea (see Appendix 1) in later symptom lists, it can be argued that these symptoms 
should also have been excluded. However, since this was not done and since these gender-
67
related gynaecological symptoms are still part of the diagnostic criteria, they were not omitted 
in the papers of this thesis. However, in order for symptoms to be directly comparable at 
baseline (1990) and follow-up (2001) in Papers I-III, only 38 symptoms could be used in the 
41-item CIDI 1.0 (see Appendix 3) and 43-item CIDI 1.2 (see Appendix 4) symptom lists. 
Likewise, the disorders in Paper II and III had to be computed directly from the 38 
unexplained symptom CIDI raw data by diagnostic algorithms according to DSM-IV criteria 
in order to be directly comparable at the two time points. Since diagnoses obtained from the 
CIDI computerized diagnostic program did not contain MSD, the diagnoses of SDs in Paper 
IV also had to be computed directly from the CIDI raw data, which examined for recency of 
MUS in three pooled categories. In effect the computation of MSD in this thesis (Paper III 
and IV), is an adaptation of the original MSD by the PRIME-MD study (Kroenke, Spitzer et 
al. 1997). A difference in methodology, which might have influenced the differences in report 
of prevalence rates of MSD, originally reported 8% (Kroenke, Spitzer et al. 1997) and by 
others 24 % (Lynch, McGrady et al. 1999) and in this thesis (Paper IV) as 14% in 2001 (Paper 
IV)
5.2.3 Prevalence 
Even though reports the existing literature of prevalence rates of SDs are quite abundant, most 
studies are based on lifetime exploration of MUS and only a few are based on current 
symptom criteria (Kroenke, Spitzer et al. 1997; Lyles, Hodges et al. 2003; Hiller, Rief et al.
2006). Wide variations in reported prevalence ranges, (Faravelli, Salvatori et al. 1997; Lynch, 
McGrady et al. 1999; De Waal, Arnold et al. 2004) could be due to differences in 
methodology and a wide variety definitions (Creed, Barsky 2004; Creed 2006a). For example, 
for SDud it is apparent that some studies define this category according to the abridged SSI-
4/6 or SSI-3/5 criteria (Escobar, Rubio-Stipec et al. 1989; Rief, Heuser et al. 1996) whereas 
others define it as a disorder at the one MUS level (Lynch, McGrady et al. 1999). Even 
figures from different epidemiological studies in the same country, for example Norway 
(Sandanger, Nygard et al. 1999; Kringlen, Torgersen et al. 2001; Kringlen, Torgersen et al.
2006) are not directly comparable due to diverging methodologies.  
Nevertheless, comparisons of prevalence rates within the same survey having a repeated 
cross-sectional design, such as the Oslo-Lofoten study are considered more trustworthy 
(Sandanger, Nygard et al. 2006). The overall 10.2% six-month prevalence rate of pooled SDs 
according to current MUS criteria presented in Paper IV may be seen as comparable to the 
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two-week 5.9 % prevalence rate of SDs previously reported from the Oslo-Lofoten study. 
Even so the comparison has some shortcomings since the CIDI 1.0, 41-item symptom list of 
1990 is somewhat different from the CIDI 1.2, 43-item symptom list of 2001 and since 
disorders examined in the SDs category were more numerous in 2001 (for example SDnos 
was not examined by the CIDI diagnostic algorithms in 1990).  
Although it is argued that the introduction of “clinical significance” in DSM-IV has 
reduced prevalence rates of any mental disorder (anxiety, depression and substance abuse) in 
the adult population (over 18 years) from an earlier 28.1% down to 18.5% (Regier, Narrow 
2002), this does not seem to be the case for SDs. In contrast, the 18.7% - 22% size and burden 
of SDs according to newer studies, also based on current criteria (Wittchen, Jacobi 2005; 
Hiller, Rief et al. 2006), give the impression of an increased prevalence rate tendency. When 
compared with previous two week 5.9% prevalence rate of SDs the Oslo-Lofoten study from 
1990, the overall 10.2% rate of severe current SDs (Paper IV) does not support an increased 
prevalence rate tendency. Although the use of severity, i.e. employing the disability 
dimension to reduce number of false-positive disorder cases, has been criticized (Wakefield, 
Spitzer 2002), it can be argued that this practice does have a practical utility purpose, when 
also considering the policy implications of epidemiologic data. When applying the severity 
criterion, the pooled prevalence rate of current SDs dropped from 24.6% to 10.2% (Paper IV).  
5.2.4 Course and stability  
Longitudinal epidemiological studies concerned with SDs are not many (Creed 2006a) and 
validation by course over time are lacking (Robins, Guze 1970; Feighner, Robins et al. 1972; 
Panzetta 1974). When considering issues of diagnostic validity, marked differences in 
outcome suggesting a diagnostic heterogeneity must be taken into account (Dennerstein 
2005). For example only a small group (mainly women) with MUS-pain are found prone to 
chronicity (Paper II), suggesting that the group of MUS-pain sufferers is not homogenous. 
Since this reveals the group of MUS-pain sufferers to be etiologically heterogeneous, it could 
be argued that a single symptom should not be representative of a disease or disorder entity 
(Dennerstein 2005). On the other hand, some mono-symptomatic physical disorders are a 
matter of considerable clinical concern, such as non-cardiac chest pain (Dammen, Bringager 
et al. 2006) and chronic dizziness (Staab 2006). Such disorders do in some cases obviously 
need to be addressed as the disease itself (Hahn 1999) based on the manifestation of the 
severity of the symptom. 
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Comparable to the overall 48% stability for the whole SDs group reported by Lieb and 
colleagues (Lieb, Zimmermann et al. 2002), stability for pooled “lifetime SDs” is found 
similar and highest (53%) by prospective consistency (Paper III). However, for current SDs, 
stability by retrospective consistency was 42% and better than for lifetime SDs (33%), and the 
measurement of agreement although good/fair (ț =0.214 (P<.001)) was best for current SDs 
(Paper III). This reflects not only an inconsistency of the CIDI instrument in detecting these 
disorders from baseline to follow-up, but likewise to the findings in Paper II for MUS-pain, 
that the course of SDs is remittent rather than chronic in nature over time. These findings are 
in clear contrast to the criteria and view of SDs having a chronic and recurrent course, in both 
the DSM-IV and ICD-10.  
5.2.5 Gender 
The purpose of introducing the terms medically unexplained, somatization and somatoform  
was to free the manifestation of unexplained symptoms from their hysteria legacy (Wool, 
Barsky 1994). However, this does not seem to be the result. Compared to other mental 
disorders, the gender differences in criteria, requiring fewer symptoms for men than for 
women, as in the SDz, SSI-4/6 and SSI-3/5 concepts are quite exceptional. 
The symptom lists used to explore whether symptoms are medically explained or not, 
are by their history (Perley, Guze 1962; Feighner, Robins et al. 1972) still stuck in the mire of 
more female symptoms being on the list (see Appendix 2 to 4). Although not the only 
explanation, this bias most likely does account for some of the tendency of women to report 
more MUS than men (Paper I) and consequently for the prevalence rates generally being 
twice as high for women (Paper IV). Generally women tend to report more symptoms than 
men at baseline, but men tend to forget more at follow-up than women (Paper I). The 
forgetting of symptoms was also related to age and symptom load, and young women had an 
increased twofold risk compared with men for having persistent MUS-pain over a long time. 
Although just a few (predominantly women) are prone to chronicity of MUS-pain at the one 
symptom level (Paper II), it is of vital importance to all clinicians to identify those at risk and 
to subsequently find adequate treatment measures. 
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5.2.6 Overlap and comorbidity  
The overlap of functional syndromes has previously been described as being so extensive that 
similarities outweigh the differences (Wessely, Nimnuan et al. 1999; Aaron, Buchwald 2001). 
In this thesis the overlap between the subtypes of disorders in the SDs category is found so 
substantial that a slight difference can only be found when classifying the disorder subtypes 
by current or lifetime criteria (Paper III). These very unclear boundaries seem to reflect not 
only the consensus opinion criteria roots of mental disorders, but also that arbitrary cut-off 
points have been superimposed on variables that are normally distributed in the population 
(Follette, Houts 1996; Kroenke, Rosmalen 2006).   
In contrast to SDs having a three-fold increased risk of co-morbid anxiety and 
depression (De Waal, Arnold et al. 2004), an even higher four to five times greater likelihood 
of having current SDs when depressed is found (Paper III and IV). In addition a two times 
risk of comorbid musculoskeletal disorders is found (Paper IV). A kinship between current 
SDs, anxiety and depression in the sharing of risk factors is also demonstrated (Paper IV).  
Altogether, only 31% of those with severe current SDs were without co-morbidity (Paper IV) 
and in this subclass psychological distress measured by the HSCL-25 score is also found 
elevated compared to those without any disorders.  
5.2.7 Predictors and risk factors  
Not all disease pathology explains bodily symptoms and not all bodily symptoms can be 
explained by disease, neither can all bodily symptoms that are not explained by disease be 
explained by psychopathology (Sharpe, Mayou et al. 2006).
Considering that the psychobiology of MUSs has been linked with depression and the 
involvement of decreased tryptophan and other serotonergic amino acids (Rief, Pilger et al.
2004), and the antidepressant mianserin found as an effective agent for treatment of patients 
with FGID (Tanum, Malt 1996), MUS-pain, might in this respect represent a real “taxon” in 
psychopathology. If this be the case, then the question is whether the CIDI instrument and the 
methods used for identifying MUS are good enough.  
Although etiological support is given in this thesis to the psychobiology of MUS being 
linked with depression (Rief, Pilger et al. 2004; Larson, Clark et al. 2004) (Paper I) the exact 
psychopathology of MUSs can not be determined. To gain such knowledge, interventions, 
neuroimaging and similar studies, in addition to epidemiological studies, such as the Oslo-
Lofoten study, are needed. Hypothetically if MUS-pain should be a real taxon in 
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psychopathology, then the question is whether the CIDI instrument and the methods used for 
identifying MUSs are good enough.  
No matter how good the identification of MUS by strict exclusion of possible medical 
disease causes is in the CIDI somatoform probing (Wittchen, Essau et al. 1993; Rubio-Stipec, 
Canino et al. 1993), this cannot make up for the fact that the presumed psychopathology 
behind MUSs has been hypothetically derived and is based on psychoanalytical theory 
(Sharpe, Mayou et al. 2006). In the long run, such preconceptions are scientifically very 
unsatisfactory, as demonstrated by the large variability in the MUS/MES distinction by Paper 
I.
5.3 Conceptual issues 
Distinguishing disorders from non-disorders, mental from physical disorders, and the problem 
of a diagnostic category being either over or under exclusive involves also conceptual issues 
(Wakefield, Spitzer 2002; Regier, Narrow 2002; Bradfield 2006; Sykes 2006). Conceptual 
issues of unexplained symptoms and their related syndromes can be traced all the way back to 
Ancient Greek medicine in the history of Hysteria. However, modern history of SDs can be 
said to have its origin in the mid 19th century beginning with the influential hysteria works of 
Briquet and Charcot (Briquet 1859; Charcot 1987) which later, under the influence of 
psychoanalytical Freudian theory (Micale 1993; Marin, Carron 2002) metamorphosed into 
somatization and SDs of the twentieth century. The controversies of medical theory, disease 
explanation and causation throughout the ages and even those facing SDs today can be seen in 
the fascinating history of SDs.  
Interestingly, Hysteria was among the psychiatric disorders found sufficiently validated 
by means of the five Feighner phases (given in Table 1) presented in 1972 (Feighner, Robins 
et al. 1972), later to be included and modified into the SDs of DSM-III (American Psychiatric 
Association 1980). Although the symptomatology for SDz concerning number of symptoms 
has changed throughout revisions of DSM, age of onset (defined as: before 30 years for 
Hysteria) and the course (chronic or recurrent for Hysteria) have not. Even the screening of 
many of the symptoms, to date has remained the very same! It is not surprising that present-
day neurologists proclaim hysteria to have never disappeared but to have lived on over two 
millennia, being seen as pseudo and psychogenic seizures in ordinary neurological practice 
among both women and men today (Trimble 2004). On the other hand, in light of the 
remnants of Hysteria and Briquet’s syndrome living on in today’s SDs, the controversy and 
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criticism of SDs not being valid enough any longer to justify their belonging to future 
classification of mental illness is not surprising (Mayou, Kirmayer et al. 2005; Bradfield 
2006; Sykes 2006; Sharpe, Mayou et al. 2006).  
Although the terms MUSs and MESs were introduced to clarify and to operationalize 
somatization in research (Melville 1987; Kirmayer, Robbins 1991), and to rid SDs of their 
hysteria legacy (Wool, Barsky 1994) the extensive gender issue connected with unexplained 
symptoms and SDs still remains today. Why only amenorrhea was abolished from the original 
59-item hysteria symptom list (Appendix 1) and dysmenorrhoea, menstrual irregularity, 
excessive bleeding, vomiting during the whole pregnancy and dyspareunia kept in the later 
lists (Appendix 3 and 4) is a relevant question. Similar to the argument that dyspareunia 
should no longer be classified as a mental disorder (Spitzer 2005) because “it makes no 
sense”, the same can be argued for all these gynaecological symptoms.  
Even though application of criterion sets and the use of structured interviews, such as 
the CIDI, to a large extent have improved the diagnostic reliability of psychiatric disorders 
(Beauchaine, Beach 2006), the studies of this thesis still casts considerable doubt on both the 
validity and reliability of MUS and their related syndromes. The MUS criteria used today to 
separate SDs from other physical disorders are definitely less clear today than when they were 
introduced (Bradfield 2006). 
5.4 Pros and cons in the DSM-V deliberations
Suggestions concerning what to do in the future are many and diverse. In spite of a collective 
agreement on all future changes being empirically based, increasing validity, reliability and 
utility of the disorder(s), strong voices have advocated a variety of outcomes, such as the 
disorders be lumped, split up, relocated within DSM-V and discarded altogether (Mayou, 
Kirmayer et al. 2005; First 2005; Kroenke 2006; Fava, Fabbri et al. 2007). In each 
classification revision, the number of diagnoses and pages grow substantially (Follette, Houts 
1996) and new dimensions of the disorders are introduced, for example disability and distress 
in the DSM-IV (Wakefield, Spitzer 2002; Regier, Narrow 2002). A completely new category 
of “interface disorders” collecting and covering all functional disorder in a multidisciplinary 
fashion (Henningsen, Zipfel et al. 2007) has also been suggested as a solution to bridge the 
symptom in the mind versus body gap (Komaroff 2001). Views from experts concerning how 
to deal with these disorders in the future cannot entirely free themselves from appearing 
tinged by their context and being somewhat country dependent (Anglo - American - German 
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– Scandinavian - Italian) (Mayou, Kirmayer et al. 2005; Kroenke 2006; Henningsen, Lowe 
2006; Fink, Toft et al. 2007; Rief, Isaac 2007; Fava, Fabbri et al. 2007), regarding how the 
field of psychosomatic medicine and research in the field is organized and funded. Although 
political pressure has been warned against as being determinative for changing DSM 
classification (Starcevic 2006), health policy issues concerning inequity in patient disability 
pensions if and when symptoms, distress and dysfunction are classified as mental disorders, 
are very central to the debate and must be taken seriously.  
Although using the term “functional” rather than “medically unexplained” may be less 
stigmatizing (Stone, Wojcik et al. 2002) by implying a malfunctioning nervous system, it does 
not really solve the problem, since the precise aetiology of MUS and the mechanisms by 
which psychopathology causes physical symptoms still remain unclear today (Rief, Pilger et 
al. 2004; Sharpe, Mayou et al. 2006). The future suggested replacement of all existing SDs, 
under the new PSD umbrella relocated on an Axes III, general medical disorders of DSM-V 
(Kroenke 2006), with a cut-off level of only one not fully explainable symptom (see Table 3), 
still leaves PSD to be established by MUSs and by exclusion criteria. Even the recommended 
PHQ-15 physical symptom list (see Appendix 2) for confirming PSD, includes symptoms of 
menstrual problems/cramps for women, and still does not solve the dilemma of how many 
symptoms to count and how really to decipher which symptoms are not fully medically 
explained.  
6. Conclusion and implications 
Classification of mental disorders should be aimed at merging disorders sharing the same 
presenting symptoms, encouraging differential diagnoses and the exclusion of general medical 
conditions, and facilitating communication between mental health professionals and also 
between health professionals and patients. Co-morbid symptoms of anxiety/depression rather 
than medically unexplained symptoms per se, should qualify the patient for a psychiatric 
diagnosis. 
Main conclusions of the thesis: 
• Lifetime symptoms are often forgotten over time. Lifetime data elicited in community 
surveys by diagnostic instruments such as the CIDI should be viewed with caution. 
Methodological errors weakening the data credibility could lead to false impressions of 
true change over time.  
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• The medically unexplained and medically explained distinction of physical symptoms is 
difficult to maintain. 
• A course of re-currency and remittance of MUS-pain is the rule rather than the exception. 
Except for a small group (mainly women) prone to chronicity, the prognosis of MUS-pain 
is relatively good. Clinicians should examine for depression when confronted with MUS-
pain patients and be aware of the increased twofold risk for women compared to men to 
have debilitating pain symptoms over a long time.  
• Prior depression and physical disease are risk factors for current SDs, but only prior 
anxiety appears to be a risk factor for lifetime SDs. However, present anxiety is a main 
risk factor associated with severe current SDs. Utilization of health care should be 
considered an outcome measure and not be part of the future SDs criteria.  
• Overlap between SDs is high (up to 100%). Diagnostic stability of current SD is better 
than lifetime SDs. Current SDs are 4 times more likely to occur among depressed 
respondents and co-morbidity of severe current SDs with anxiety/depression and/or 
musculoskeletal disorders is 70%. The overall prevalence rate of severe current SDs in 
2001 is 10%.  
6.2 Future research and classification 
Although psychiatric and somatic disorders should be diagnosed separately, it is important to 
arrive at a consensus between the medical specialities concerning diagnoses. It is still 
necessary to base diagnoses on consensus opinion of experts, but they should also 
increasingly be based on empirical evidence concerning, reliability, validity and utility. Future 
diagnostic criteria of SDs should be based on current symptoms, and not on lifetime. The 
criteria should also be based on positive symptomatology, and not on exclusion criteria. The 
same should apply to other outcome measures such as utilization of health care. The criteria 
for women and men should be the same. Follow-up studies and further validation of recently 
suggested multidimensional and multidisciplinary functional somatic syndromes criteria for 
SDs are clearly needed.  
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Appendix
Appendix 1. Hysteria (Briquet’s syndrome) and 59-item physical symptoms list  
Diagnostic criteria a - both criteria A and B are required:  
A.  A chronic or recurrent illness beginning before age 30, presenting with dramatic, vague or 
complicated medical history.
B. At least 25 symptoms for “definite” diagnosis and 20 to 24 symptoms for a “probable” diagnosis in 
at least 9 of the following groups:
Group 1  
1. Headaches 32. Diarrhea 
2. Feeling sickly most of life 33. Constipation* 
Group 2 Group 6 
3. Blindness 34. Abdominal pain 
4. Paralysis 35. Vomiting 
5. Anesthesia 
6. Aphonia Group 7 
7. Fits or convulsions 36. Dysmenorrhea 
8. Unconsciousness 37. Menstrual irregularity 
9. Amnesia 38. Amenorrhea* 
10. Deafness 39. Excessive bleeding 
11. Hallucinations (in absence of psychosis)* 
12. Urinary retention Group 8 
13. Trouble walking 40. Sexual indifference 
14. Other conversion symptoms 41. Frigidity 
 42. Dyspareunia 
Group 3 43. Other sexual difficulties 
15. Fatigue* 44. Vomiting during all nine months of pregnancy or 
hospitalized for hyperemesis gravidarum 
16. Lump in throat  
17. Fainting spells Group 9 
18. Visual blurring 45. Back pain 
19. Weakness 46. Joint pain 
20. Dysuria 47. Extremity pain 
 48. Burning pains of the sexual organs, mouth, or 
rectum 
Group 4 49. Other bodily pains 
21. Breathing difficulty  
22. Palpitation Group 10 
23. Anxiety attacks* 50. Nervousness* 
24. Chest pain 51. Fears* 
25. Dizziness 52. Depressed feelings* 
 53. Need to quit working or inability to carry on regular 
duties because of feeling sick* 
Group 5 54. Crying easily* 
26. Anorexia* 55. Feeling life was hopeless* 
27. Weight loss* 56. Thinking a good deal about dying* 
28. Marked fluctuations in weight* 57. Wanting to die* 
29. Nausea 58. Thinking of suicide* 
30. Abdominal bloating 59. Suicide attempts* 
31. Food intolerances  
C. No other diagnosis can be made to explain the symptoms 
a
 Diagnostic criteria by Feighner et al. in 1972 (Feighner, Robins et al. 1972) based on the work by 
Perley and Guze, 1962 (Perley, Guze 1962)
* Eliminated symptoms in the DSM-III list (American Psychiatric Association 1980)
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Appendix 2. Patient Health Questionnaire 15-Item Somatic Symptom Severity Scale (PHQ-
15)
During the past 4 weeks, how much have you been bothered 
by any of the following problems?  
0
Not bothered 
at all 
1
Bothered 
a little 
2
Bothered 
a lot 
1. Stomach pain      
2. Back pain    
3. Pain in your arms, legs or joints (knees, hips, etc.)    
4. Menstrual cramps or other problems with your periods 
[women only]    
5. Headache    
6. Chest pain    
7. Dizziness    
8. Fainting spells    
9. Feeling your heart pound or race    
10. Shortness of breath    
11. Pain or problems during intercourse    
12. Constipation, loose bowels or diarrhea      
13. Nausea, gas or indigestion    
14. Feeling tired or having low energy    
15. Sleeping trouble     
Total score (from 0 to 30) a:
a
 Severity of symptoms score, ranging from 0 to 30. The PHQ-15 is a somatic symptom subscale 
derived from the full 20-item self-administered Patient Health Questionnaire (PHQ) of the PRIME-MD 
(Pfizer Inc, New York, NY) a brief instrument developed for making criteria based diagnoses of mental 
disorders in primary care (Spitzer, Williams et al. 1994).  
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Appendix 3. CIDI 1.0 Somatoform section, 41-item physical symptoms list 
i) Pain a:
1. abdominal pain  21. numb feeling in arm/leg 
2. back pain 22. paralysis 
3. joint pain  23. lost voice 
4. leg/arm pain  24. seizure 
5. chest pain  25. faint 
6. headache  26. unconscious 
7. painful menstruation*  27. amnesia 
8. urination pain  iii) Sexual and other symptoms c:
9. genital pain  28. double vision  
10. other place pain  29. short breath  
ii) Gastrointestinal and pseudo-neurological b: 30. weakness  
11. vomiting 31. blotchy skin  
12. continuous vomiting during pregnancy* 32. bad taste in mouth  
13. nausea 33. urinate too often  
14. diarrhoea  34. unable to urinate  
15. excessive gas 35. numbness 
16. food intolerance 36. lump in throat 
17. blindness 37. irregular menstruation* 
18. blurred vision 38. excessive menstrual bleeding* 
19. deafness (39. dizziness) d
20. trouble walking (40. heart pounding, beating hard) d
 [41. often felt sickly] e
a
 1. Pain category, pooled for recency of MUS(s); last month, last six months, over six months ago and 
within last year, over one year ago. 
b
 2. Gastrointestinal and pseudo-neurological, pooled for recency of MUS(s) as in a.
c
 3. Sexual and other symptoms, pooled for recency of MUS(s) as in a.
d
 Not in A2, 2001 list 
e
 Symptom excluded  
* Women only 
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Appendix 4. WHO-CIDI 1.2 Somatoform section, 43-item physical symptoms list 
i) Pain a:
1. abdominal pain  22. paralysis 
2. back pain 23. lost voice 
3. joint pain  24. seizure 
4. leg/arm pain  25. faint 
5. chest pain  26. unconscious 
6. headache  27. amnesia 
7. painful menstruation* iii) Sexual and other symptoms c:
8. urination pain  28. double vision  
9. genital pain  29. short breath  
10. other place pain  30. weakness  
ii) Gastrointestinal and pseudo-neurological b: 31. blotchy skin  
11. vomiting 32. bad taste in mouth  
12. continuous vomiting during pregnancy* 33. urinate too often  
13. nausea 34. unable to urinate  
14. diarrhoea  35. numbness  
15. excessive gas 36. lump in throat 
16. food intolerance 37. irregular menstruation* 
17. blindness 38. excessive menstrual bleeding* 
18. blurred vision (39. sexual problems/impotence) d
19. deafness (40. sexual indifference) d
20. trouble walking (41. pain during sexual intercourse) d
21. numb feeling in arm/leg (42. sex not enjoyable) d
 [43. often felt sickly] e
a
 1. Pain category, pooled for recency of MUS(s); last month, last six months, over six months ago and 
within last year, over one year ago. 
b
 2. Gastrointestinal and pseudo-neurological, pooled for recency of MUS(s) as in a.
c
 3. Sexual and other symptoms, pooled for recency of MUS(s) as in a.
d
 Not in A1, 1990 list 
e
 Symptom excluded  
* Women only 
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Appendix 5. Hopkins Symptom Checklist (HSCL-25) anxiety and depression subscales   
The respondent is requested to assess how much, on a scale from (1) not at all to (4) very much, she/he has 
been bothered with the following symptoms (during the last week, including at present):
Anxiety subscale items (1–10)
1. Suddenly scared for no reason  
2. Feeling fearful  
3. Faintness, dizziness or weakness 
4. Nervousness or shaking inside 
5. Heart pounding or racing 
6. Trembling 
7. Feeling tense or keyed up 
8. Headaches 
9. Panic attacks or spells of fear  
10. Feeling restless, unable to sit still  
Depression subscale items (11–25)
11. Feeling low in energy  
12. Blaming oneself for things 
13. Crying easily 
14. Loss of sexual interest or pleasure 
15. Poor appetite 
16. Difficulty falling asleep or staying asleep 
17. Feeling hopeless about the future 
18. Feeling blue 
19. Feeling lonely 
20. Thoughts of ending your life 
21. Feeling of being trapped or caught 
22. Worrying too much about things 
23. Feeling no interest in things 
24. Feeling everything is an effort 
25. Feelings of worthlessness
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Appendix 6. Fifteen-item physical disorders list, in 1990/2001 Follow-up 
Disorders recorded in 1990 and 2001as present or not a:
15-item physical disorders list: 
1.   Diabetes 
2.   Heart stroke, angina, hypertension 
3.   Stroke, cerebral haemorrhage 
4.   Bronchitis, asthma, hay fever, allergic eczema 
5.   Psoriasis 
6.   Rheumatic disease, arthritis, ankylosing spondylitis 
7.   Arthrosis 
8.   Tendonitis, muscle knots 
9.   Lumbago, sciatic back pain 
10. Epilepsy, neurological disorder 
11. Gastrointestinal disorders, stomach ulcer, gastritis 
12. Blood diseases, anaemia 
13. Kidney, liver, bile/gall bladder disease 
14. Cancer 
15. Other physical diseases 
a
 1990/2001 Follow-up (Paper I, II, III) – in 2001 only disorders with impairment (2) moderate to (3) 
severe were included 
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Appendix 7. Thirteen-item physical disorders list and four-item musculoskeletal disorders list, 
in 2001 Sample 
The respondent is requested to assess how much, on a scale from (1) a little (2) moderate to (3) 
severe she/he has been affected (impaired in daily life, activities, work) by the following disorders 
(during the last year) a:
13-item physical disorders list: 4-item musculoskeletal disorders list: 
1. Diabetes 
2. Heart stroke, angina, hypertension 
3. Stroke, cerebral haemorrhage 
4. Bronchitis, asthma, hay fever, allergic eczema 
5. Psoriasis 
6. Rheumatic disease, arthritis, ankylosing 
spondylitis 
7. Arthrosis 
8. Epilepsy, neurological disorder 
9. Gastrointestinal disorders, stomach ulcer, gastritis 
10. Blood diseases, anaemia 
11. Kidney, liver, bile/gall bladder disease 
12. Cancer 
13. Other physical diseases 
1. Tendonitis, muscle knots 
2. Fibromyalgia, chronic fatigue 
3. Neck/shoulder myalgia, including whiplash  
4. Lumbago, sciatic back pain/myalgia 
a
 2001 Sample (Paper IV) – only disorders with impairment  (2) moderate to (3) severe included 
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Appendix 8. Fifty-two item Stressful Life Events Scale  
Report of events 12 months preceding the interview and affected by the event (1) a little (2) 
moderately (3) severely a.
1. Large changes in duties at work 
2. Conflict at work 
3. Large business problems 
4. Dismissed from work 
5. Without employment, laid off 
6. Spouse or living partner laid off 
7. Started an education 
8. Broken off an education 
9. Serious financial difficulties 
10. Serious illness or accident (own) 
11. Admitted to hospital (own) 
12. Abortion or miscarriage 
13. Menopause 
14. Given birth 
15. Something of great importance lost or 
destroyed 
16. Death of close friend 
17. Death of close relative 
18. Death of grandchild 
19. Death of child 
20. Death of father 
21. Death of mother 
22. Death of spouse/living partner 
23. Moved, migrated 
24. In trouble with the law 
25. Other legal difficulties 
26. Children moved out of home 
27. Children with emotional problems 
28. Children with alcohol or narcotic problems  
29. Spouse/living partner with emotional problems 
30. Spouse/living partner with alcohol or narcotic 
problems 
31. Serious conflict with children 
32. Separation or divorce in children 
33. Conflict with neighbour 
34. Significant conflict with another (not neighbour 
or cohabitant) 
35. Seriously ill friend 
36. Seriously ill grandchild 
37. Seriously ill child 
38. Seriously ill parent 
39. Seriously ill relative 
40. Seriously ill spouse/living partner 
41. Married or become cohabitant 
42. Relationship problems, in marriage or with living 
partner 
43. Separated, divorced or broken up living partner 
relationship 
44. Unfaithful (self or spouse/living-partner) 
45. Abused 
46. Become separated from persons of significance 
(other than death) 
47. Housing/residential problems 
48. Change of housing/residence 
49. Retired, resigned or on welfare pension 
50. Home residence suddenly ruined 
51. Started new job 
52. All other events of importance 
a
 In 1990, severity of life events from (1) to (3) was not recorded. The 52-item list is a reduced and 
adapted version of Paykel and Mangan’ s 63-item schedule (Paykel, Mangen 1980) 
